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ABSTRACT 
 Pancreatic β-cells regulate blood glucose by secreting insulin in response to 
nutrients. The development of Type 2 Diabetes (T2D) is characterized by elevated insulin 
secretion in the fasted state and a failure to adequately respond to nutrient influx, 
particularly glucose. Current dogma states that insulin resistance is the initiating event in 
the development of T2D, with compensation by β-cells necessary to maintain glucose 
homeostasis. An alternative model, which will be a central theme throughout this thesis, 
is that hypersecretion of insulin is the initiating and sustaining event in the development 
of T2D.  
 The underlying cause of insulin hypersecretion is unclear. Determining this is 
important in order to test this alternative model as a viable target for prevention and 
treatment of T2D. Because of the association between obesity and hyperinsulinemia, we 
hypothesized that exposure of the β-cell to high levels of nutrients stimulates insulin 
hypersecretion. We found that chronic incubation of β-cells in high glucose and/or oleate, 
which mimics nutrient conditions in obesity, lowered the half-maximal response for 
glucose to stimulate insulin secretion. The degree of the left-shift correlated with lipid 
stores. We determined that heightened sensitivity of granule exocytosis to Ca2+ was 
	 vii 
driving this left-shift. Thus glucose, while not necessarily abnormal in obesity, may cause 
hypersecretion of insulin due to altered sensitivity of the β-cell to this secretagogue. Iron 
stores are increased in obesity and are predictive of T2D development. We found that 
iron acutely stimulated both basal and glucose-stimulated insulin secretion (GSIS) in a 
reactive oxygen species dependent manner. Interestingly, iron did not increase insulin 
secretion via Ca2+ influx. Thus, both iron and glucose/oleate induce insulin 
hypersecretion via an aspect of the triggering pathway that is not Ca2+, the putative 
triggering signal. Previous work in our laboratory documented that exogenous mono-
oleoyl-glycerol, an endogenous lipid signaling molecule and food additive, increases 
basal insulin secretion. We found that inhibition of monoacylglycerol lipase, which 
increases cellular monacylglycerol species, reduced GSIS, possibly via a reduction in 
long-chain CoA. Collectively, our works supports the hypothesis that chronic exposure to 
high nutrient levels drives insulin hypersecretion in obesity.  
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CHAPTER ONE: General Introduction 	 The current epidemic of T2D afflicting affluent and emerging nations presents 
one of the most challenging healthcare crises of the 21st century. The economic burden 
placed on the healthcare system by T2D is enormous and will undoubtedly continue to 
grow if the status quo is maintained. Current data estimate that one in five dollars spent 
on health care in the U.S. can be directly or indirectly linked to diabetes (American 
Diabetes, 2013). Troublingly, T2D, once referred to as adult-onset diabetes, is now being 
diagnosed in younger age demographics (Imperatore et al., 2012). Taken together, the 
urgency needed to develop new prevention measures and improved therapeutic strategies 
cannot be overstated. Current pharmacological therapies used to treat T2D can control the 
disease in most patients over the short-term, but are unable to reverse it despite evidence 
from bariatric surgery patients that such a reversal is indeed possible (Nannipieri et al., 
2011; Pories et al., 1995). 
 T2D is characterized by chronically elevated blood glucose. While not acutely 
harmful to patients, the condition places them at increased risk for several serious 
conditions including cardiovascular disease, microvascular disease, kidney disease, 
cancer and neuropathy (Sheetz and King, 2002). In healthy people, blood glucose is 
controlled within a very tight range (4.5-5.0 mM glucose) with only acute spikes of mild 
hyperglycemia (~7 mM) following ingestion of a carbohydrate rich meal. This is 
achieved by the coordination of several key organs, most notably the pancreas, liver and 
gut. The hormone insulin, secreted by the pancreatic β-cell, spikes following a meal and 
acts on the insulin receptor in liver, muscle and adipose tissues to increase nutrient uptake 
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and storage. Insulin resistance (IR) occurs when the body fails to properly respond to 
elevated insulin, thus preventing proper storage and raising circulating nutrient levels.   
Models of the progression of T2D 
 Elevated fasting insulin, IR and β-cell dysfunction are all hallmarks of T2D 
(Kahn, 2003). The disease is almost always diagnosed in patients that are overweight or 
obese, though in specific regions of the world the average body mass index of diagnosis 
is much lower (Nakagami et al., 2003). Current dogma regarding the progression of T2D 
postulates that weight gain or a genetic predisposition leads to IR in peripheral tissues.  
Hyperinsulinemia (HI), a state in which plasma insulin levels are chronically elevated, 
then ensues as a compensatory response needed to prevent hyperglycemia. This 
compensatory response is presumed to be due to an expansion of the β-cell mass, i.e. the 
number of pancreatic islets and/or β-cells per islet. Only when β-cell failure occurs does 
impaired glucose tolerance advance to T2D (Nolan et al., 2006a; Prentki and Nolan, 
2006). This model, outlined in Figure 1.1, has persisted despite the inability of knockout 
models of pure IR to recapitulate the phenomenon of HI (Bluher et al., 2002; Bruning et 
al., 1998; Okamoto et al., 2004). Additionally, IR and HI always seem to be present 
together and display a well-characterized hyperbolic relationship, making it difficult to 
ascertain which one precedes the other (Retnakaran et al., 2008). The longitudinal studies 
in humans needed to definitively determine the order of metabolic abnormalities that 
precede abnormal glucose tolerance and T2D simply have not been done. Interestingly, in 
rhesus monkeys that become naturally obese and diabetic, HI precedes IR (Hansen and 
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Bodkin, 1990). Additionally, it has been shown in rodents that high-fat feeding causes 
insulin hypersecretion prior to the onset of IR (Bonen et al., 2015).  
Evidence in support of the HI model of T2D 
 An alternative model (Figure 2.1) stipulates that a high nutrient diet, like that 
commonly found in developed countries, leads to both obesity and HI. HI promotes 
obesity by increasing lipid deposition in adipose and other tissues. Mice with only half 
the amount of insulin gene present in the β-cell gain weight at a slower rate and have 
improved glucose tolerance on a high-fat diet (Mehran et al., 2012). Obesity drives HI by 
bathing β-cells in a constantly high nutrient environment. Thus, in this model, HI can 
both promote and sustain obesity, and vice versa.  
The concept that insulin hypersecretion may underlie a primary abnormality in the 
progression of T2D has not been seriously considered despite several lines of evidence in 
support of this. First, indisputable evidence from both human and animal models have 
demonstrated that prolonged exposure to elevated insulin results in IR and impaired 
glucose tolerance (Miles et al., 1998; Rizza et al., 1985). Conversely, inhibition of insulin 
secretion via administration of an ATP-sensitive K+ (KATP) channel agonist improves 
insulin sensitivity and glucose tolerance in animal models and humans with HI 
(Alemzadeh et al., 1998; Carr et al., 2003; Zdravkovic et al., 2005). Insulin-induced IR 
arises from down regulation of the insulin receptor and defective signal transduction 
through the insulin-signaling cascade due to desensitization (Miles et al., 1998). Also the 
accumulation of lipid species via insulin’s lipogenic activity is likely to induce IR 
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(Samuel et al., 2010). HI causes lipid accumulation in hepatocytes via activation of 
peroxisome proliferator-activator receptor-γ (Steneberg et al., 2015).  
Second, Roux-en-Y gastric bypass surgery rapidly normalizes HI independent of 
changes in insulin sensitivity or significant weight loss while simultaneously improving 
glucose tolerance and reversing T2D in some patients (Camastra et al., 2011; Reed et al., 
2011). While only a correlation can be drawn between the normalization of HI and the 
rapid resolution of T2D documented in patients post-surgery, it presents an interesting 
observation given the currently accepted model of T2D. It is not known if these effects 
are due to dietary changes associated with Roux-en-Y gastric bypass or are a direct result 
of the surgery. However, simply fasting also reduces HI and normalizes the response of 
the β-cell to glucose in diabetic patients (Lim et al., 2011). This is associated with a 
reduction in pancreatic triacylglycerol (TAG) content, likely due to increased fat 
oxidation, a normal evolutionary response to starvation. Lastly, evidence supporting this 
alternative theory comes from ethnic populations with particularly high susceptibilities 
for developing T2D including African Americans and Pima Indians. These populations 
have increased HI not accounted for by IR (Aronoff et al., 1977; Arslanian et al., 2002). 
A prospective study in Pima Indians identified the degree of HI as an important predictor 
of which patients would go on to develop T2D (Weyer et al., 2000).  
Clinical implications of T2D treatments 
 Resolving whether high insulin may be pathological rather than compensatory is 
of critical importance as many of the current therapeutic and pharmacological targets for 
treating T2D attempt to further elevate insulin levels, possibly exacerbating the disease. 
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The vast majority of current therapeutics used to treat T2D either target IR or attempt to 
coax that β-cell into secreting more insulin. The first line defense, metformin, has long 
been shown to be effective at both preventing and treating T2D (Clarke and Duncan, 
1968). The mechanism(s) via which metformin acts are still unknown, though it has been 
shown to effect both peripheral tissues and β-cells in isolation (Leclerc et al., 2004; Owen 
et al., 2000). Unfortunately, subsets of patients on metformin still develop T2D.  
Second-line pharmaceutical agents include sulfonylureas, which increase insulin 
secretion in an unregulated manner. Recent evidence indicates that use of these drugs 
may be more harmful than helpful long-term (Aston-Mourney et al., 2008). Newer 
classes of drugs include incretin mimetics that increase insulin secretion from the β-cell, 
but only when glucose is elevated. In this way these drugs do not stimulate insulin 
secretion when inappropriate, like during hypoglycemia, and are therefore safer and have 
proven more effective (Russell, 2013). Interestingly, none of these drugs have shown the 
ability to reverse progression of T2D, only to improve glucose homeostasis. Thus, it is 
entirely possible that increasing insulin secretion may not be helpful long-term, and quite 
possibly leads to exhaustion of a β-cell that is already hyper secreting insulin (Abdulreda 
et al., 2016).  
Additional therapeutics for treating T2D include insulin sensitizers like 
thiazolidinediones, which act by storing FFAs as neutral lipid. While effective at 
improving glucose homeostasis, these drugs also have potentially harmful long-term 
consequences for cardiovascular disease (Lipscombe et al., 2007). It is interesting to 
speculate that IR may be protective in obesity. If hypersecretion of insulin is an initiatory 
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rather than compensatory event in T2D, a reduction in insulin sensitivity would be an 
appropriate response from the body in order to prevent hypoglycemia, a potentially 
acutely life threatening situation. Additionally IR may be protective against further 
weight gain, as insulin is a potent anabolic hormone that not only regulates glucose 
homeostasis but also protein and lipid synthesis and storage. Insulin itself is given to 
patients either in combination with other drugs or by itself. However, new data suggests 
that while insulin helps to improve HbA1C levels in patients, it may also increase risk of 
cardiovascular death. In the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial, a large prospective study testing the hypothesis that aggressive 
glycemic control through insulin therapy would reduce cardiovascular deaths, the 
opposite was observed (Skyler et al., 2009). 
Taken together, it is clear that an alternative hypothesis to the origins of T2D is 
warranted, as current therapies cannot reverse the disease. 
Dyslipidemia in obesity and T2D 
 Altered lipid profiles are characteristic of humans with obesity and T2D. 
Dyslipidemia of obesity consists of elevated fasting and postprandial triglycerides, free 
fatty acids (FFA), low-density lipoproteins and reduced high-density lipoproteins (Opie 
and Walfish, 1963; Vijayaraghavan, 2010). The increased FFA of obesity is thought to be 
due to the enlargement of adipose stores, reduced clearance and impaired capacity of 
insulin to exert its antilipolytic effect (Jensen et al., 1989; Nestel and Whyte, 1968). 
While the origin and role of FFAs in insulin resistance and metabolic syndrome have 
been questioned (Karpe et al., 2011), it is generally accepted that FFAs are elevated in 
		
7 
obesity. This has led researchers within the β-cell field to test the hypothesis that FFAs 
may be in part responsible for the myriad of obesity-related changes in the β-cell. From 
this, the concept of glucolipotoxicity (GLT) has emerged (Prentki and Corkey, 1996). 
This work has focused on the long-term effects of exposure to elevated FFAs and 
glucose, mainly as it relates to the β-cell dysfunction (reduced insulin secretion) and loss 
observed in T2D. Much less has been done to address if this same model can address the 
early stages of progression to T2D, namely, if this may contribute to hypersecretion of 
insulin and HI. This will be a focus of the work presented in this thesis. 
Origins of HI 
Insulin clearance 
 Insulin is cleared primarily by hepatocytes in a receptor-mediated manner 
(Duckworth and Kitabchi, 1981). Insulin is secreted into the portal vein and immediately 
travels to the liver, where approximately 50-70% is cleared within the first pass 
(Duckworth and Kitabchi, 1981). The possible contribution of impaired insulin clearance 
to the observed HI of obesity has long been recognized (Meistas et al., 1983). The degree 
of liver fat accumulation correlates very strongly with serum insulin levels in man 
(Kotronen et al., 2007a; Kotronen et al., 2007b). In the perfused rat liver, insulin 
clearance was significantly lower in livers from older, heavier rats and when the perfusate 
was supplemented with free fatty acid (FFA) (Svedberg et al., 1991). This phenomenon 
also occurs in vivo in dogs when fatty acids (FA) are administered either through the 
portal vein or peripherally (Yoshii et al., 2006). Interestingly, weight loss in obesity, 
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which is commonly associated with a concomitant reduction in liver fat, has been found 
to increase insulin clearance (Escobar et al., 1999).  
β-cell mass 
 While reductions in insulin clearance may contribute to HI, comprehensive 
studies in humans have documented unequivocally that insulin secretion rates are higher 
in obesity (Polonsky et al., 1988a; Polonsky et al., 1988b). The term β-cell mass 
encompasses several concepts including hypertrophy (increase in islet cell size), 
hyperplasia (increase in islet cell number) and neogenesis (cells derived from 
progenitors).  Increased β-cell mass has been widely observed in genetically obese and 
diet-induced obese rodent models (Dalboge et al., 2013; Jetton et al., 2005; Steil et al., 
2001). Human studies have also documented increases in β-cell mass, albeit to a lesser 
extent than observed in rodents (Butler et al., 2003; Mezza et al., 2014). Nutrients, 
including glucose and FAs, have been implicated in this compensatory process in rodents 
(Steil et al., 2001; Terauchi et al., 2007; van Citters et al., 2002). Additionally, hormones 
like insulin and insulin-like growth factors seem to play an important role in β-cell mass 
expansion.  These two arms are not mutually exclusive and seem to converge on the 
insulin-receptor substrate-2 pathway (Withers et al., 1998). Mice that are deficient in 
insulin-receptor substrate-2 do not exhibit increased β-cell mass in response to a high-fat 
diet, while those deficient in insulin-receptor substrate-1 do (Burks and White, 2001). A 
recently discovered hormone betatrophin seems to correlate with β-cell mass in rodents, 
although this finding has been called into question (Gusarova et al., 2014; Yi et al., 
2013). 
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Insulin content 
 Insulin biosynthesis is tightly coupled to GSIS such that stores are maintained 
within a tight range under normal conditions. For example, glucose stimulates not only 
insulin secretion but also insulin gene expression and translation (Kulkarni et al., 2011; 
Leibiger et al., 2000). Insulin gene transcription generates preproinsulin mRNA, which is 
subsequently translated to proinsulin at ribosomes on the rough endoplasmic reticulum 
(ER). Proinsulin then undergoes oxidative folding in which three disulfide bonds are 
formed in the lumen of the ER. Proinsulin is subsequently transported to the golgi 
apparatus where it packaged into insulin granules and cleaved of a 31 amino acid 
polypeptide called C-peptide (Fu et al., 2013). Multiple groups have shown that FAs can 
inhibit insulin transcription and translation (Hagman et al., 2008; Kelpe et al., 2003). This 
is not a result of increased neutral lipid synthesis, as overexpression of diglyceride 
acyltransferase does not influence proinsulin mRNA levels (Kelpe et al., 2002). Only 
saturated FAs including palmitate elicit this effect leading to the conclusion that ceramide 
synthesis is imperative in this process (Moore et al., 2004).  Additionally, infusion of 
FFA in vivo has been shown to deplete insulin stores by stimulating insulin secretion 
without simultaneously increasing insulin biosynthesis, as glucose does (Bollheimer et 
al., 1998).   
 Genetic models of obesity including db/db mice have increased pancreatic 
proinsulin mRNA prior to the onset of diabetes. Orland et al. noted a strong correlation 
between pancreatic proinsulin and serum insulin levels, implying a possible connection 
(Orland and Permutt, 1987). These authors documented a decline in insulin mRNA 
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corresponding to the onset of hyperglycemia. A recent study found that two strains of 
db/db mice had dramatically increased rates of proinsulin biosynthesis, which was 
reversible upon exposure of islets to a normal glucose concentration in vitro (Alarcon et 
al., 2016). It should be noted that leptin, the signaling of which is ablated in db/db mice, 
has been shown to inhibit insulin biosynthesis (Pallett et al., 1997; Seufert et al., 1999).  
Diet-induced obesity via high-fat feeding decreases islet proinsulin mRNA levels (Capito 
et al., 1992). The discrepancy between these models is unclear at this time, but may have 
to do with the genetic background of the rodent (Andrikopoulos et al., 2005).  
Insulin hypersecretion 
 A functional change within one of more of the secretory pathways of the β-cell 
has also been proposed to contribute to the observed HI of obesity (Kautzky-Willer et al., 
1992). The pancreas is in part regulated by the central nervous system, and disruption of 
the ventral medial hypothalamus has been reported to cause HI in rodents (Ahren, 2000; 
Berthoud and Jeanrenaud, 1979). However, the fact that isolated islets retain basal 
hypersecretion of insulin suggests that something intrinsic to the β-cell is likely to be the 
primary cause (Getty-Kaushik et al., 2009). The glycolytic enzyme hexokinase, the 
expression and activity of which is normally suppressed in β-cells, has been documented 
in islets incubated in high lipid conditions and genetic models of obesity (Cockburn et al., 
1997; Liu et al., 1998). This lowers the threshold for stimulated insulin secretion by 
glucose due to the low Km of hexokinase. Increased lipid metabolism in the form of 
lipolysis and glycerolipid/free fatty acid (GL/FFA) cycling has also been proposed to be 
an important player in the manifestation of insulin hypersecretion of obesity (Nolan et al., 
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2006a). This study interestingly documented that only islets from obese animals 
displayed a stimulatory response to exogenous palmitate and forskolin at basal glucose. 
Important regulators of insulin secretion 
 In the late 19th century, Dr. Paul Langerhans identified clusters of cells within the 
pancreas that we now know to be the source of insulin. Dr. Frederick Banting and 
Charles Best first identified the hormone insulin in the year 1921. These innovative 
researchers showed that a pancreatic extract could lower blood glucose in diabetic dogs 
and humans (Karamitsos, 2011). These Islets of Langerhans are highly vascularized and 
compose approximately 1-2% of the total pancreatic volume. Islets are made up of 
several cells types including α- and β-cells, which secrete glucagon and insulin, 
respectively. Insulin is the bodies’ principal anabolic hormone and is secreted in response 
to a rise in blood nutrient levels. Insulin acts on peripheral tissues including liver, muscle 
and adipose to increase macronutrient nutrient uptake and storage.  
Classical model for GSIS 
 Glucose is the most important secretagogue for insulin secretion.  The pathway by 
which glucose stimulates insulin secretion is well characterized. Rodent β-cells express 
the high Km glucose transporter GLUT-2, which allows passage of physiological levels of 
glucose into the cell. Interestingly, human β-cells predominantly express GLUT-1, which 
has a lower Km than GLUT-2 (McCulloch et al., 2011). The high Km glucose 
phosphorylating enzyme glucokinase (GK) allows the cell to sense fluctuations in 
extracellular glucose and respond appropriately. It is believed that this enzyme controls 
the typical sigmoidal dose-response curve for GSIS (Matschinsky et al., 1998). 
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Metabolism of glucose through glycolysis leads to a rise in pyruvate, which is transported 
into the mitochondria and converted to acetyl-CoA. A rise in NADH generated by 
pyruvate and the tricarboxyclic acid cycle increases respiration eventually resulting in an 
increase in the cytosolic ATP/ADP ratio. This leads to closure of KATP channels, 
depolarization of the plasma membrane and opening of voltage-dependent Ca2 channels 
(VDCC). The subsequent rise in intracellular Ca2+ concentration ([Ca2+]i) ‘triggers’ the 
fusion of insulin granules with the plasma membrane. A secondary pathway ‘amplifies’ 
the secretion induced by triggering, though the signals that cause this are not as 
straightforward. The observation that insulin secretion still exhibits a dose-response to 
glucose even at a fixed [Ca2+]i has lead to the notion that glucose is capable of generating 
a number of these amplifying signals (Gembal et al., 1992). This also indicates that Ca2+ 
is a permissive signal and is not responsible for the dose-response curve generated by 
glucose, a assertion we have previously published (Heart et al., 2006).  
Role of cAMP 
 Several candidate signals have emerged that likely contribute to the amplification 
pathway. The rise in ATP associated with high glucose also serves as a substrate for 
several reactions including the generation of cyclic adenosine monophosphate (Lee et al.) 
by the enzyme adenylate cyclase. cAMP has been shown to directly interact with the 
exocytotic protein Epac2, a guanine nucleotide exchange factor which serves as a cellular 
cAMP sensor and increases the readily releasable pool of insulin granules in response to 
glucose (Seino and Shibasaki, 2005). A protein kinase A (PKA)-dependent mechanism 
for the enhancement of insulin secretion by cAMP has also been proposed (Lester et al., 
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1997). The hormones GLP-1 and GIP increase stimulated insulin secretion in part by 
raising cAMP levels (Green et al., 2004). This can account for over half of the insulin 
secretion when nutrients are taken orally (Nauck et al., 1986). 
Acute effect of FA  
 FA acutely enhances GSIS, with saturated and monounsaturated species being the 
most potent (Stein et al., 1997). FAs originate from the diet or adipose stores and can act 
via receptors on the β-cell like GPR40 and GPR120, or enter the cell upon which they are 
converted to a CoA ester. Glucose also stimulates lipolysis from intracellular lipid stores 
(Winzell et al., 2006). This process in indispensable for normal GSIS, as islets from 
fasted animals do not exhibit GSIS unless supplemented with FA (Stein et al., 1996). 
Lipid species shown to be contributors to FA-induced insulin secretion include but are 
not limited to monoacylglycerol (MAG), diacylglycerol (DAG) and long chain (LC)-
CoA. The targets of these lipid species will be discussed in more detail in subsequent 
sections but include exocytotic proteins, kinases and ion channels. 
ROS and insulin secretion 
 Reactive oxygen species (ROS) have recently been identified as a critical 
signaling molecule for insulin secretion (Pi et al., 2007). Pi et al. demonstrated that   
hydrogen peroxide (H2O2) stimulates insulin secretion at basal glucose. They also showed 
that glucose stimulates ROS production, probably by increasing flux through the electron 
transport chain, and that antioxidants blunt GSIS. A subsequent study demonstrated that 
inhibition of electron transport produced ROS from the mitochondria and stimulated 
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insulin secretion (Leloup et al., 2009). Additionally, the plasma membrane enzyme 
NAD(P)H oxidase, which generates superoxide upon activation, has been shown to be 
important in GSIS (Newsholme et al., 2009). Several pieces of evidence point to H2O2 as 
the effector ROS signal in nutrient/secretion coupling. First, β-cells express normal 
amounts of superoxide dismutase, but low levels of the H2O2 consuming enzymes 
catalase and glutathione peroxidase (Lenzen et al., 1996). Second, H2O2 is a much more 
stable than other species of ROS and can permeate membranes (Veal et al., 2007). 
Exocytotic Machinery of the β-cell 
 The proteins involved in exocytosis in the β-cell are similar to what is found in 
neuronal cells, which release neurotransmitters in response to stimuli. A key component 
of the exocytotic machinery are soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor (SNARE) proteins. These evolutionarily conserved proteins regulate 
vescicle membrane fusion and exocytosis (Gerst, 1999). The assembly of a core fusion 
complex including vescicle associated membrane protein 2 and the plasma membrane 
SNAREs syntaxin-1a and synaptosomal-associated protein 25 (SNAP25) is integral in 
regulated exocytosis. Other exocytotic proteins regulate these SNARE proteins to either 
promote or inhibit exocytosis (Gerst, 2003). Munc-13a binds to MAGs and DAGs and 
alters the confirmation of syntaxin1a from a ‘closed’ to ‘open’ state, allowing the 
formation of the core fusion complex (Betz et al., 1997). Synaptogamin IX is expressed 
in β-cells and knockout of this exocytotic protein in β-cells inhibits glucose- and 
sufonylurea-induced insulin secretion (Iezzi et al., 2004). Synaptotagmin contains two 
Ca2+ binding sites and is thought to be the primary mechanism by which Ca2+ influx is 
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sensed in the β-cell. Synaptotagmin binds to SNAP25 and syntaxin-1a and possibly 
mediates assembly of the core fusion complex and zippering of the secretory granule with 
the plasma membrane (Chapman, 2002).  
FA metabolism in β-cells 
Role of Malonyl-CoA in nutrient partitioning 
 β-cells contain many small lipid droplets distributed throughout the cytosol, 
whereas other islet cell types do not (Vernier et al., 2012). FAs can either be derived from 
the lipid droplets via lipolysis, or from the circulation.  β-cells also express the enzyme 
lipoprotein lipase and thus have access to circulating lipoprotein triglycerides (Pappan et 
al., 2005). FAs serve as an important source of energy for β-cells, particularly during 
times of fasting. Similar to hepatocytes and myocytes, the β-cell regulates lipid 
partitioning via malonyl-CoA (Prentki et al., 2002).  When circulating glucose/nutrient 
levels are high, TCA cycle intermediates are also elevated.  Citrate exits the mitochondria 
and is converted to acetyl-CoA in the cytosol. Acetyl-CoA is then carboxylated by acetyl-
CoA carboxylase (ACC) to form malonyl-CoA, which inhibits FA oxidation by binding 
to carnitine palmitoyl transferase I (CPT1). Inhibition of CPT1 increases synthesis of 
complex lipids, for which malonyl-CoA is the precursor, and elevates cytosolic LC-CoA 
by preventing their oxidation.  Conversely, when energy levels are low, such as during 
fasting, the enzyme AMP-activated protein kinase is activated because of an increased 
AMP/ATP ratio. This results in the phosphorylation of ACC, inactivating it, leading to 
reduced cellular malonyl-CoA levels (Ruderman and Prentki, 2004).   
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 The cross-talk between glucose and FA metabolism also occurs at the level of 
gene expression. Chronic exposure of β-cells to elevated glucose increases lipogenic gene 
expression (Roche et al., 1998). Additionally, glucose provides a glycerol backbone onto 
which FAs can be esterified in order to synthesize complex lipids (Reshef et al., 2003). 
Thus, studies have noted that chronic exposure to FAs has only a marginal affect unless 
glucose is concomitantly elevated (Briaud et al., 2001).          
GL/FFA cycling 
 β-cells express the enzymes for synthesis and breakdown of TG.  GL/FFA cycling 
encompasses the simultaneous breakdown and synthesis of complex lipid species. Lipid 
synthesis begins with the formation of lysophosphatidic acid from glycerol-3-phosphate 
and LC-CoA, catalyzed by the enzyme glycerol 3-phosphate acyltransferase. 
Lysophosphatidic acid is then converted to phosphatidic acid (a DAG molecule) by 
esterification of another FA from LC-CoA via the enzyme acylglycerol-3-phosphate 
acytransferase. Another FA is then esterified via LC-CoA to form TAG by the enzyme 
DAG acyltransferase. Lipid synthesis can also begin with MAGs, as the enzyme MAG 
acyltransferase converts MAG to DAG (Hayashi et al., 2014). On the lipolysis end, TAG 
breakdown by adipose triglyceride lipase generates DAG. Subsequent hydrolysis to 
MAG by hormone-sensitive lipase yields MAG. MAG can be broken down by either 
MAG lipase (MGL) or α/β hydrolase domain-6 (ABHD6). β-cells do not express glycerol 
kinase and thus glycerol derived from the breakdown of MAG is released from the cell 
(MacDonald and Marshall, 2000). Experiments labeling both glycerol and FAs have 
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demonstrated that labeling is depleted much faster in the former, indicating that these are 
predominantly recycled (Nolan et al., 2006b).  
Depletion of intracellular lipid droplets via fasting or inhibition of lipase activity 
with the global lipase inhibitor orlistat inhibits GSIS (Mulder et al., 2004; Stein et al., 
1996). This strongly suggests an important role for lipid signaling in insulin secretion. As 
a neutral lipid with no known signaling properties, TAG is not known to have any acute 
affect on insulin secretion. DAG is known to influence insulin secretion via multiple 
mechanisms. First, DAG binds to the exocytotic protein Munc 13-1 to stimulate 
exocytosis. Mice with a reduction of Munc 13-1 in β-cells have reduced insulin secretion 
(Kwan et al., 2006). Additionally, DAG can bind to protein kinase C (PKC), and β-cells 
express many typical and atypical PKC isoforms. Data exists both refuting and 
supporting a role for PKC in GSIS.  The role of MAG has been less extensively 
researched but has yielded some intriguing results. Exogenous exposure of β-cells to 
mono-oleoyl-glycerol increases basal insulin secretion in a ROS dependent manner 
(Saadeh et al., 2012). Interestingly, while global inhibition of lipase activity reduces 
insulin secretion, a recent paper has demonstrated that inhibition of ABHD6 enhances 
GSIS (Zhao et al., 2014). MAG also has affinity for Munc 13-1, and enhances insulin 
secretion by binding to this exocytotic protein.  
LC-CoA and insulin secretion 
Cytosolic LC-CoA is increased following stimulation with glucose both as a 
result of GL/FFA cycling and inhibition of CPT-1. The role of LC-CoA in insulin 
secretion is controversial. Evidence supporting comes from pharmacological and genetic 
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alteration of the malonyl-CoA/CPT1 pathway. Overexpression of a malonyl-CoA 
insensitive form of CPT1 increases FA oxidation at any glucose concentration and 
reduces GSIS (Herrero et al., 2005). Inhibition of ATP-citrate lyase, the enzyme that 
catalyzes the conversion of citrate to acetyl-CoA, reduces malonyl-CoA levels and GSIS 
(Flamez et al., 2002). Overexpression of malonyl-CoA decarboxylase, which degrades 
malonyl-CoA, has been reported to have no effect on GSIS, although it does inhibit FA-
induced insulin secretion (Mulder et al., 2001; Roduit et al., 2004). The specific target of 
LC-CoA has not been elucidated. It has been observed that LC-CoA may act to directly 
increase exocytosis (Deeney et al., 2000). In support of this, there are multiple acylation 
sites on exocytotic proteins including the putative Ca2+ sensor synaptotagmin (Heindel et 
al., 2003). LC-CoA also activates multiple forms of PKC in β-cells (Yaney et al., 2000). 
A review of the various roles of LC-CoA in cell signaling can be found here (Faergeman 
and Knudsen, 1997). 
β-Cell Failure: Role of FA 
 It has only recently been recognized that the final step in the pathway towards 
T2D is a failure of β-cells to adequately respond to stimulatory glucose (Kahn, 2003). 
Both genetic models and humans with T2D appear to have a corresponding reduction in 
β-cell mass, which may contribute to the relative insulin deficiency (Butler et al., 2003). 
The relative roles of reductions of mass versus a functional defect in T2D have been 
debated (Meier and Bonadonna, 2013). Chronic FA exposure has been shown to 
consistently cause a reduction in GSIS. Some work has shown that the increased 
‘oxidative stress’ associated with excess nutrients is responsible for this reduction 
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(Oprescu et al., 2007). The fact that β-cells express low levels of antioxidant enzymes it 
thought to make them particularly vulnerable to these stressors (Nolan and Prentki, 
2008). This can lead to the process of apoptosis (Lupi et al., 2002; Shimabukuro et al., 
1998). Additionally, ER stress, which leads to the unfolded protein response and 
apoptosis, has been shown to be caused by both glucose and elevated LC FAs in β-cells 
(Cnop et al., 2007; Hou et al., 2008). Interestingly, in the case of FAs it has also been 
observed that only saturated FAs, particularly palmitate, can cause activation of the 
unfolded protein response (Karaskov et al., 2006). Use of palmitate in vitro in the study 
of processes related to lipotoxicity may be misleading as cells cannot synthesize 
triacylglycerol (TAG) without unsaturated FAs (Moffitt et al., 2005). This leads to 
crystallization of the ER and apoptosis, a situation that a normal β-cell would be unlikely 
to experience in vivo. 
 In addition to the relative insulin deficiency associated with β-cell failure, several 
other defects are known to be involved. β-cells normally secrete insulin in an oscillatory 
manner, which is thought to enhance the ability of insulin to stimulate nutrient uptake in 
peripheral tissues. The oscillations occur with a period of roughly 5 to 15 minutes. 
Coordination of these oscillations is controlled via both intra-islet and intra-pancreas 
mechanisms (Porksen et al., 2002). Within the β-cell, it is believed that metabolic 
oscillations in metabolism, which result in calcium oscillations, play a key role in 
secretory oscillations (Tornheim, 1997). Other metabolic secretory signals oscillate in 
sync with calcium oscillations (Deeney et al., 2001), The oscillatory pattern of insulin 
secretion is lost in T2D (Lang et al., 1981). A second important defect in β-cell failure is 
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an increase in the ratio of secreted proinsulin/insulin. It is believed that this defect results 
from insufficient time for granule maturation rather than a defect in processing enzymes 
(Alarcon et al., 1995). However, it has also been reported that chronic exposure of β-cells 
to FAs may disrupt posttranslational processing of proinsulin by inducing a reduction in 
activity of prohormone convertase enzymes (Furukawa et al., 1999). 
Iron and T2D 
 Iron is a transition metal that plays a critical role in many biological processes.  In 
mammals, iron must be incorporated in the diet, though significant stores exist in 
erythrocytes, macrophages and hepatocytes (Pantopoulos et al., 2012). Iron can exist in 
multiple oxidation states, including ferrous (Fe2+) and ferric (Fe3+), which is critical to its 
many biological functions.  Iron mainly serves as a cofactor in iron-containing proteins 
and uses it’s ability to redox cycle to carry out these functions. Some of these functions 
include oxygen binding via hemoglobin, electron transport during oxidative metabolism, 
and DNA synthesis among others (Pantopoulos et al., 2012). While redox cycling is vital 
for the ability of iron to catalyze many reactions and processes, it also can lead to the 
generation of certain potent species of ROS (Winterbourn, 1995).  When iron is present 
with hydrogen peroxide (H2O2) and superoxide (O2-), it yields hydroxyl radicals (OH-), 
which can cause lipid peroxidation and DNA damage.  This process is called the Fenton 
chemistry (Winterbourn, 1995). Because of its susceptibility to generating ROS, iron 
levels are very tightly regulated at both the level of absorption in the intestine and entry 
into cells. 
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Cellular regulation of iron 
 Ferrous iron enters enterocytes through divalent-metal transporter 1 (DMT1) and 
exits via ferroportin. Upon exiting, iron is oxidized and bound to transferrin, which 
transports it through blood to its receptor transferrin receptor 1. Receptor-mediated 
endocytosis allows entry of iron into the cell upon which iron is released via DMT1 
following acidification of the endosome.  Iron is then directed to the mitochondria or to 
the cellular iron-binding protein ferritin, which comprises the labile iron pool and serves 
as a nonreactive storage compartment for iron within the cell (Simcox and McClain, 
2013).               
 High iron intake leads to the upregulation of the hormone hepcidin, which is 
secreted by hepatocytes.  Hepcidin causes the internalization and degradation of the iron 
transporter ferroportin, which prevents iron in the diet from being released to circulation 
(Nemeth et al., 2004).  Within the cell, increases in the labile binding pool cause the 
release of iron regulatory proteins from within transferrin receptor mRNA leading to its 
degradation and reducing influx of iron into the cell (Simcox and McClain, 2013).  
Circulating ferritin can be used as a marker for iron stores within the body.      
Iron overload and T2D 
Epidemiological evidence suggests that iron stores have a positive correlation 
with T2D while low iron stores appear to be protective against development of the 
disease (Ascherio et al., 2001; Medalie et al., 1975; Salonen et al., 1998).  Despite the 
multiple feedback mechanisms regulating iron levels in humans, there is a wide range of 
‘normal’ serum ferritin for both men (30-300 ng/mL) and women (15-200 ng/mL) 
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(Fleming et al., 2001).  Those at the high end of the ‘normal’ level have a risk of 
developing diabetes that is similar to that seen for obesity (Kriska et al., 2003).  Multiple 
studies have shown that this increased iron load can arise from the diet, particularly when 
consumed in the form of highly absorbable heme iron (Fleming et al., 2002; Qiu et al., 
2011).  Phlebotomies have shown promise as a treatment option for patients with T2D 
and high iron levels (Fernandez-Real et al., 2002). Additionally, the development of 
gestational diabetes has is associated with increased iron load (Lao et al., 2001).    
It is difficult from these epidemiological studies to show that iron is causative in 
this association.  However, genetic mutations leading to iron overload have shown an 
important role for iron in β-cell function and development of T2D.  For example, patients 
given regular transfusions for treatment of Thalassemia, a mutation in hemoglobin that 
prevents effective oxygen binding, have iron overload and have increased risk of 
developing T2D (Vogiatzi et al., 2009).  Most studies have attributed this to a reduced 
capacity to secrete insulin with concomitant IR (Arrigo et al., 1998; Jaruratanasirikul et 
al., 2008; Messina et al., 2002).  HI has been observed in a number of studies and has 
been attributed to both hypersecretion and reduced hepatic insulin extraction 
(Dmochowski et al., 1993; Merkel et al., 1988).  Other studies have documented 
increased IR, with HI due to increased insulin secretion and reduced hepatic insulin 
extraction.  Patients with Hereditary Hemochromatosis (HH), who harbor a recessive 
mutation in the HFE gene and cannot stimulate hepcidin expression, have high iron load 
(Pietrangelo, 2010).  People with HH have a 30-60% chance of developing T2D, which is 
well above average (Powell and Yapp, 2000).  Most studies have found that in patients 
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with HH, insulin secretion is significantly reduced in both patients diagnosed with T2D 
and in those with impaired glucose tolerance (Abraham et al., 2006; McClain et al., 
2006).  A number of these studies have documented increases in insulin secretion 
following phlebotomy (Abraham et al., 2006; Hatunic et al., 2010).  There are conflicting 
results in regards to the role of insulin sensitivity in HH, with some showing increased IR 
after phlebotomy (Abraham et al., 2006), and others showing reduced IR. 
Insulin secretion and iron 
It is difficult from these epidemiological studies to show that these effects are 
specifically due to the β-cell, as T2D is a complex disease involving multiple organ 
systems.  Animal models of obesity and T2D in which iron is restricted via diet or 
chelated have reduced HI, normalized glucose tolerance and improved β-cell function 
(Cooksey et al., 2010).  In contrast, another study using Otsuka Long-Evans Takushima 
fatty rats showed that iron chelation or phlebotomy increased insulin secretion, possibly 
by inhibiting apoptosis of β-cells (Minamiyama et al., 2010).  It is difficult for these to 
directly attribute these results to an iron effect on the β-cell, as iron has also been shown 
to cause IR, which has been hypothesized to cause insulin hypersecretion (Fargion et al., 
2005).  Mice lacking the cellular iron transporter DMT1 have defective GSIS from 
isolated islets, highlighting a potential role for iron in GSIS independent of other organ 
systems (Hansen et al., 2012).  
Goals of the Thesis 
We hypothesize that HI may be a primary cause of T2D; however, the origins of 
β-cell hypersecretion of insulin in obesity remains to be elucidated. Thus, therapeutically 
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targeting HI has remained difficult due to fact that the only pharmacological agents that 
can do so, KATP-channel agonists, also reduce insulin secretion when it is needed. Should 
a pathway(s) be identified that differentiates basal from stimulatory secretion, it could be 
targeted as a potential therapeutic to normalize HI without disrupting GSIS. This thesis 
will address in detail three aspects of the regulation of GSIS and how they may apply to 
the known pathological abnormalities present in prediabetes and T2D. 
1) Chapter Two will determine how chronic exposure to excess nutrients 
in the form of LC FA and glucose alters the insulin content and dose-
response curve for GSIS. 
2) Chapter Three will assess how pharmacological inhibition of MGL 
effects basal insulin secretion and the ability of glucose to acutely 
enhance insulin secretion.  
3) Chapter Four will investigate the effect that acute exposure to iron has 
on basal and GSIS. 
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Figure 1.1. Conventional model for the progression of T2D development.  
In this model, weight gain causes IR in peripheral tissues including muscle, liver and 
adipose tissue. β-cells compensate by increasing mass and/or secretory capacity to 
maintain glucose homeostasis. Prolonged requirement for increased insulin secretion 
eventually leads to β-cell failure, or an inability to respond adequately respond nutrient 
ingestion. This results in hyperglycemia and T2D.  
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Figure 2.1. Alternative model for T2D progression with a focus on HI.  
A high nutrient environment akin to a ‘western diet’ results in obesity in insulin 
hypersecretion. These two states can potentially fuel the other, as insulin is a principal 
anabolic hormone and obesity bathes the β-cell in nutrients which causes hypersecretion 
of insulin. HI causes insulin resistnace in peripheral tissues, potentially as a 
compensatory response to prevent hypoglyceimia. Sustained hypersecretion of insulin 
eventually results in β-cell failure and T2D.  
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ABSTRACT 
HI is elevated plasma insulin at basal glucose. Impaired glucose tolerance is associated 
with HI, though the exact cause and effect relationship remains poorly defined. We tested 
the hypothesis that HI can result from an intrinsic response of the β-cell to chronic 
exposure to excess nutrients, involving a shift in the concentration dependency of GSIS. 
INS-1 (832/13) cells were cultured in either a physiological (4 mM) or high (11 mM) 
glucose concentration with or without concomitant exposure to oleate. Isolated rat islets 
were also cultured with or without oleate. A clear hypersensitivity to sub-maximal 
glucose concentrations was evident in INS-1 cells cultured in excess nutrients such that 
the 25% of maximal (S0.25) GSIS was significantly reduced in cells cultured in 11 mM 
glucose (S0.25 = 3.5 mM) and 4 mM glucose with oleate (S0.25 = 4.5 mM) compared to 4 
mM glucose alone (S0.25 = 5.7 mM). The magnitude of the left shift was linearly 
correlated with intracellular lipid stores in INS-1 cells (r2 = 0.97). We observed no 
significant differences in the dose responses for glucose stimulation of respiration, 
NAD(P)H autofluoresence or Ca2+ responses between left and right-shifted β-cells. 
However, a left-shift in the sensitivity of exocytosis to Ca2+ was documented in 
permeabilized INS-1 cells cultured in 11 versus 4 mM glucose (S0.25 = 1.1 and 1.7 µM, 
respectively). Our results suggest the sensitivity of exocytosis to triggering is modulated 
by a lipid component, the levels of which are influenced by the culture nutrient 
environment. 
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INTRODUCTION 
 Obesity is associated with a marked elevation in insulin secretion under both 
fasting and nutrient-stimulated conditions, even though glucose tolerance may be normal 
(Polonsky et al., 1988b). This phenomenon manifests as HI, and has been classically 
ascribed a compensatory response by the pancreatic β-cells under conditions of systemic 
IR to maintain normal glucose homeostasis (Prentki and Nolan, 2006). Alternatively, the 
hypothesis that chronically elevated insulin may be a cause rather than consequence in 
the progression of T2D has been previously suggested (Corkey, 2012a, b; Shanik et al., 
2008). Chronically elevated insulin has been shown to induce IR by promoting lipid 
accumulation in peripheral tissues (Ning et al., 2011) and down regulating its own 
receptor, particularly in the liver (Miles et al., 1998; Russell et al., 1987). Thus, 
understanding the mechanisms by which HI manifests in the context of obesity and 
nutrient excess will help to identify potential targets needed to test this alternative prequel 
of T2D.  
Many hypotheses have been proposed to account for the HI observed in obesity, 
including reduced hepatic insulin extraction (Kotronen et al., 2007a; Meistas et al., 1983), 
and increased β-cell number and/or mass (Weir et al., 2001). The observation that C-
peptide concentrations are consistently found to be elevated in obesity signifies that while 
reduced hepatic extraction may contribute to HI, increased secretion is clearly present 
(Polonsky et al., 1988b). Increases in β-cell mass have been documented in both diet-
induced and genetic models of obesity. However, it remains unclear how much this β-cell 
mass increase contributes to HI as islets from these animals also have reduced insulin 
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content (Andrikopoulos et al., 2005; Zhou et al., 1999). Interestingly, gastric bypass has 
been shown to quickly normalize HI in obese patients with and without T2D, prior to 
significant changes in insulin sensitivity or substantial weight loss (Reed et al., 2011). 
Thus, because of the rapid nature of this reduction, functional changes seem likely to 
contribute to HI in addition to possible changes in β-cell mass.  
The ability of β-cells to sense glucose is critical for normal β-cell function 
(Matschinsky et al., 1998). The consensus pathway of GSIS includes both triggering and 
amplification (Henquin, 2011). Increased glucose metabolism in the β-cell following a 
rise in glucose results in an elevation of the ATP/ADP ratio, closure of KATP channels, 
depolarization of the plasma membrane and activation of VDCCs. The subsequent rise in 
[Ca2+]i triggers fusion of insulin granules to the plasma membrane resulting in exocytosis 
(Henquin, 2011). Other metabolic signals derived from glucose amplify secretion when 
[Ca2+]i is elevated. These signals include but are not limited to LC-CoA, ATP, DAG, 
MAG and cAMP (Prentki et al., 2013).  
Growing interest has been expressed in the concepts of glucotoxicity (Bensellam 
et al., 2012) (chronically elevated glucose), lipotoxicity (Unger and Zhou, 2001) 
(chronically elevated lipid) and GLT (Poitout et al., 2010; Prentki and Corkey, 1996) 
(combination of elevated glucose and lipid) to explain the β-cell dysfunction observed in 
T2D. Most studies in this area have focused on the reduced GSIS observed following 
exposure of β-cells to these conditions (Gohring et al., 2014; Oprescu et al., 2007; Tsuboi 
et al., 2006; Zhou and Grill, 1994). Whether the reduction in GSIS develops as a result of 
a defect in the pathway(s) leading to insulin secretion or a depletion of insulin stores is 
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controversial. Normally, insulin synthesis and secretion are tightly coupled such that 
stores are maintained within a narrow range. Glucose and other secretagogues stimulate 
both insulin secretion and synthesis by enhancing the translation of insulin mRNA to 
proinsulin (Skelly et al., 1998). In contrast, it is known that LC FAs can deplete insulin 
stores by promoting secretion of insulin while simultaneously inhibiting proinsulin 
synthesis (Bollheimer et al., 1998; Skelly et al., 1998). Additionally, multiple reports 
have documented the ability of excess lipid to inhibit insulin gene transcription both in 
vitro (Kelpe et al., 2003) and in vivo (Hagman et al., 2008).  It has also been recognized 
that culture in excess nutrients enhances basal secretion, which has been difficult to 
reconcile with the reduced maximal secretion. Few studies have attempted to characterize 
insulin secretion at intermediate glucose concentrations under these conditions, despite 
the fact that they are likely more physiologically relevant. Understanding how excess 
nutrients alter the dose-response of GSIS may help to elucidate how β-cells adapt and 
ultimately fail in T2D.  
Herein we have documented a relationship between β-cell culture conditions and 
subsequent glucose sensitivity. We found that culture in excess nutrients reduces insulin 
content, increases lipid stores, and left-shifts the concentration dependence of GSIS. This 
shift appears to be due to a difference in the sensitivity of exocytosis to the triggering 
Ca2+ signal. 
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EXPERIMENTAL PROCEDURES 
Ethics Statement − This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals by the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee at Boston University Medical Center (Boston University Medical 
Center Animal Welfare Assurance: A-3316-01) 
Islets Isolation/Culture − Islets were isolated from male Sprague-Dawley rats (150-250 
grams) as described previously (Cunningham et al., 1996). Islets were cultured overnight 
in 35 mm dishes in RPMI 1640 containing 11 mM glucose, 10% FBS, 50 IU/mL 
penicillin and 50 µg/mL streptomycin in the absence of phenol red. Islets were then 
cultured in 35 mm dishes in RPMI 1640 with or without oleate for 48 hours. Oleate 
(Sigma, St. Louis, MO) was diluted in DMSO and complexed to FBS at 57°C while 
vortexing. The oleate:BSA ratio was approximately 3.5:1 for 0.1 mM oleate, 5:1 for 0.15 
mM oleate and 7:1 for 0.2 mM oleate.  
 Human islets were cultured in 5.5 mM glucose RPMI supplemented with 10% 
FBS. Islets were then picked and placed into control culture media supplemented with 
1% BSA or 0.5 mM palmitate/0.5 mM palmitate complexted to 1% BSA at 5.5 or 11 mM 
glucose. Islets were hand picked and placed into these conditions for 24 hours after which 
they were dissociated with accutase (Sigma, St. Louis, MO). 1000 cells were then seeded 
into 96-well conical bottom plates and spun 1000 RPM for 5 minutes, after which they 
were incubated in the same media as during the 24 hour incubation period for 48 
additional hours. Insulin secretion and assay were carried out as for rat islets. 
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INS-1 Cell Culture − INS-1 (832/13) cells (Hohmeier et al., 2000) were cultured as 
described previously (Saadeh et al., 2012). Glucose was added to RPMI 1640 without 
glucose to achieve 4 mM glucose where indicated. Culture of cells for >2 weeks in a 
particular glucose concentration (4 or 11 mM) was considered ‘chronic’.  
Insulin Secretion − INS-1 cells were grown in 48- and 96-well plates (Corning, Corning, 
NY) to an approximate density of 240,000 and 100,000 cells per well, respectively, after 
which insulin secretion in static incubations was assessed as previously described 
(Saadeh et al., 2012). The Krebs-Ringer bicarbonate buffer (KREBS) used in experiments 
contained (in mM) 119 NaCl, 4.6 KCl, 5 NaHCO3, 2 CaCl2, 1 MgSO4, 0.15 Na2HPO4, 0.4 
KH2PO4, 20 HEPES, 0.05% BSA, pH 7.4. Cells were lysed in cold PBS containing 0.1% 
Triton X-100 (Sigma, St. Louis, MO) and 25 mM NaOH for insulin content. Islets were 
picked and spotted in Matrigel (BD Biosciences, Bedford, MA) at 30 islets per well in a 
48-well plate. Islets were pre-incubated in KREBS containing 3 mM glucose for 30 
minutes at 37oC. After removal of the pre-incubation buffer, test solutions were added 
and the islets were incubated for 1 hour at 37oC. Insulin was measured using the HTRF 
insulin assay (CisBio, Bedford, MA). The software program GraphPad Prism 5 
(GraphPad Software Inc., La Jolla, CA) was used to determine the half-maximal (S0.5), 
from which the quarter-maximal (S0.25) and tenth-maximal (S0.1) were derived. Islet 
perifusions were performed as described previously (Cunningham et al., 1996).  
Nile Red − Nile red (Sigma, St. Louis, MO) was reconstituted in DMSO and added to 
cells at a final concentration of 3.1 µM to image the intracellular lipid stores (Greenspan 
et al., 1985). Following a 15-minute incubation, the solution was removed and cells were 
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imaged in KREBS using a Nikon TE200 microscope with an excitation/emission 
wavelength of 488 nm/515 nm at 20X magnification. ImageJ (imagej.nih.gov/ij) was 
used to analyze the images in order to quantify the fluorescence as a percent of the total 
intracellular area.  
GK Measurement − The method used to measure GK activity from cell-extracts has been 
described previously (Lenzen et al., 1987). Briefly, cells were sonicated and centrifuged 
at 4,500 g for 5 minutes. GK activity was measured in the supernatant as NADPH 
generated from the conversion of glucose-6-phosphate to 6-phosphogluconate and from 
the conversion of 6-phosphogluconate to Ribulose-5-phosphate using an F-2000 
Fluorescence Spectrophotometer (excitation 340 nm/emission 460 nm) (Hitachi, Tokyo, 
Japan). The GK reaction was initiated with glucose. Glucose was increased in a stepwise 
manner and the slope was used to calculate the relative activity. Total protein in the 
supernatant was measured by bicinchoninic acid method (Thermo Fisher Scientific, 
Waltham, MA) and absorbance (562 nm) was measured using a Tecan Infinite M1000 
plate reader (Tecan, Männedorf, Switzerland). For intact cell GK activity experiments, 
cells were plated in 384-well glass bottom plates to a density of 30,000 cells per well 
(Thermo Fisher Scientific, Waltham, MA) and treated as in insulin secretion experiments 
prior to the test period. 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose 
(2-NBDG) (Invitrogen, Carlsbad, CA) was incubated with cells at 1% of the total glucose 
concentration in KREBS for 15 minutes, a time point determined to be within the linear 
range of uptake. Cells were then washed twice and fluorescence (465 nm/540 nm 
excitation/emission) was detected in the Tecan plate reader.     
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Oxygen Consumption − O2 consumption was assessed in INS-1 cells using the Seahorse 
Extracellular Flux Analyzer XF24 machine (Seahorse Bioscience, Billerica, MA) as 
described previously (Saadeh et al., 2012). Briefly, cells were grown in Seahorse V.7 24-
well culture plates to a density of approximately 120,000 cells per well using culture 
conditions described above. Cells were incubated prior to the experiment in the same 
manner as insulin secretion experiments and measurements were performed in KREBS. 
Oligomycin (5 µM), carbonyl cyanide-4-trifluoromethoxy phenyl-hydrazone (FCCP) (2.5 
µM) and antimycin (10 µM) were injected while maintaining the glucose concentration at 
4, 6 or 8 mM to calibrate. 
Redox Measurement − INS-1 cells were plated in 4-quadrant glass bottom dishes 
(Greiner Bio-One, Frickenhausen, Germany) and cultured as described above to a density 
of 30,000 cells per quadrant. A deconvolution wide-field epifluorescence microscope 
(Nikon, Tokyo, Japan) was used to measure NAD(P)H autofluorescence in INS-1 cells. 
This method cannot distinguish between NADH and NADPH, hence the designation of 
NAD(P)H (Rocheleau et al., 2004). Prior to measurement, cells were pre-incubated as 
described for insulin secretion. Next, 300 µL of KREBS containing 2 mM glucose but 
without BSA was added to the cells and equilibrated for 5 minutes at 37oC. 
Autofluoresence (340 nm/460 nm excitation/emission) was collected at 20X 
magnification. Then, 150 µL of KREBS with concentrated glucose was added to each 
quadrant to bring the glucose to the desired concentration. NaCN (2 mM final) plus 
concentrated glucose (12 mM final) was added to each quadrant to obtain maximum 
reduction. Since FCCP (2 µM) was found to interfere with the subsequent NaCN 
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response, maximal and minimal fluorescence signals at basal glucose were obtained in 
separate traces. Images from each trace were analyzed by subtracting the background and 
creating regions of interest from a cell mask that were applied to the entire time course 
using ImageJ. Islets were spotted in Matrigel in 4-quadrant dishes and were treated 
similarly to INS-1 cells, though FCCP was not used because of differences in basal (3 
mM glucose) fluorescence within islets of the same condition. This was likely in part due 
to size differences among islets, in which anoxia can be observed in the core of larger 
islets and may contribute to artificially high baseline levels of NADH (Obi-Tabot et al., 
1993). Thus, the scale that was used to analyze islets was fluorescence at basal (3 mM) 
glucose (0%, minimum NAD(P)H) and NaCN (100%, maximum NAD(P)H). 
Ca2+ Determination – [Ca2+]i was measured using fura-2 AM (Invitrogen, Carlsbad, CA) 
as previously described (Saadeh et al., 2012). Briefly, INS-1 cells and whole islets were 
loaded with fura-2 (2 µM) for 30 minutes in KREBS with 0.1% pluronic acid (Thermo 
Fisher Scientific, Waltham, MA) on 35 mm glass bottom dishes (MatTek, Ashland, MA). 
A 15-minute cleavage period was then initiated following removal of the fura-2. Imaging 
was performed on an Olympus DSU spinning disk confocal microscope at 20X 
magnification and 37°C. Fluorescent images were captured every 10 seconds with 
wavelengths of 340 nm/380 nm dual excitation and 510 nm emission. Data were analyzed 
using ImageJ. Oscillatory pattern was assessed using the software program Optimized 
Optimal Segments (OOPSEG) as described previously (Deeney et al., 2001).  
Glycerol Release − Glycerol was measured enzymatically using glycerokinase and α-
glycerophosphate dehydrogenase from the supernatant of insulin secretion experiments.  
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NADH produced in the assay was detected by luminescence as previously described 
(Peyot et al., 2004). For TAG measurement, a lipase cocktail (Sigma, St. Louis, MO) was 
used to first liberate the glycerol from the TAG backbone following extraction in a RIPA 
buffer.  
Permeabilized Cell Exocytosis  – INS-1 cells were pretreated as in secretion experiments 
except without the 30-minute KREBS incubation. Cells were washed once with a 
permeabilization buffer containing (in mM) 220 Mannitol, 70 Sucrose, 10 KH2PO4, 5 
MgCl2, 2 HEPES, 1 EGTA with 0.2% BSA. Cells were then incubated in the same buffer 
with 2 nM XF PMP permeabilizing agent (Seahorse Bioscience, Billerica, MA) at 37oC 
for 5 minutes. Cells were then incubated in an ATP regenerating buffer with different 
free [Ca2+] for 15 minutes as described previously (Deeney et al., 2000). Ca2+ 
concentrations were set using Theo Schoenmakers’ Chelator program 
(http://maxchelator.stanford.edu) and verified with a Ca2+-sensitive electrode (Orion, 
Boston, MA). 
Statistics − The data are presented as the mean of independent experiments ± S.E.M. 
Statistical significance was determined by two-tailed Student’s t test or by a one-way 
analysis of variance (ANOVA) followed by Bonferroni’s post hoc test where indicated. A 
p-value of <0.05 (*) was considered significant, (#) indicates a p-value of <0.01 and (+) 
indicates a p-value of <0.001. 
 
 
 
 	38	
RESULTS 
Culture of pancreatic islets in excess lipid altered both insulin content and secretion  
Figure 1.2A shows that a 48-hour incubation of isolated rat islets in standard 
culture media (11 mM glucose) with 0.2 mM oleate reduced the total insulin content by 
approximately 80%. The depletion of insulin content was prevented by co-incubation 
with the KATP channel agonist diazoxide (DZ), which inhibits membrane depolarization 
and Ca2+ influx. This indicates that hypersecretion of insulin plays an important role in 
the reduction of insulin content under GLT (Bollheimer et al., 1998), though we cannot 
rule out a contribution of DZ preventing β-cell apoptosis, a process known to be 
dependent on a rise in Ca2+. 
To examine the effect of preserving the insulin content on insulin secretion under 
conditions of GLT, we performed a series of islet perifusion experiments (Fig. 1.2B). 
Control islets (blue) not incubated in oleate or DZ displayed very low basal secretion at 3 
mM glucose. In response to a rise in the glucose concentration from 3 to 11 mM, a 
classic, bi-phasic pattern of GSIS was observed. Upon a further increase to 15 mM 
glucose, the islets exhibited greater insulin secretion. Islets cultured in DZ (green), but 
tested following DZ washout, exhibited identical secretion to control islets (Fig. 1.2B), 
which suggested that sustained membrane polarization had no effect on β-cell secretory 
function.  
Islets cultured in oleate (red) displayed elevated basal secretion compared to 
controls, had a blunted response to 11 mM glucose and showed no further increase in 
secretion at 15 mM glucose, indicative of a left-shift in GSIS (Fig. 1.2B). In islets 
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cultured in oleate plus DZ (purple), which have normal insulin content, a much different 
pattern of secretion was observed. These islets displayed greatly enhanced basal secretion 
of insulin compared to both control islets and islets cultured in oleate alone. They 
responded to 11 mM glucose and demonstrated enhanced secretion compared to control 
islets. Similar to islets cultured in oleate alone, those co-cultured with oleate and DZ did 
not exhibit a further response when the glucose concentration was raised to 15 mM (Fig. 
1.2B). When expressed as a percent of content secreted, the secretion from islets treated 
with oleate alone was superimposable to that of islets treated with oleate plus DZ (Fig. 
1.2C), suggesting that under GLT, normalization to insulin content is critical for correctly 
assessing the rate of insulin exocytosis. The fold GSIS, assessed by dividing 1st phase 
secretion (average between 16.1-17.2 min) by basal secretion (average from 0-12.6 min), 
was reduced in islets cultured in oleate (~4-fold) compared to control islets (~15-fold) 
(Fig. 1.2D). However, this result was due to increased basal secretion, not reduced GSIS. 
These results also indicated that islet insulin content was an important determinant of 
secretion but not glucose sensitivity. 
Rat islets cultured in a high lipid environment exhibited left-shifted GSIS 
We next wanted to examine whether chronic exposure to FA induced a left-shift 
in the concentration dependence of GSIS. In order to prevent a dramatic loss in insulin 
content as was observed with 0.2 mM oleate, we incubated islets in standard culture 
media (11 mM glucose) with and without 0.1 mM oleate for 48 hours. Insulin content in 
islets incubated with 0.1 mM oleate was not significantly different than control islets 
(p=0.52, Fig. 2.2A). The disparity between this result and the large difference in insulin 
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content observed with culture of islets in 0.2 mM oleate likely results from a substantial 
increase in FFA concentration due to the rise in the FA:BSA ratio (3.5:1 and 7:1 for 0.1 
and 0.2 mM oleate, respectively). Similar to our results in the perifusions, islets cultured 
in oleate displayed a left-shifted dose-response for GSIS as demonstrated by increased 
responsiveness to submaximal glucose concentrations (6, 7, 8, 11 mM) (Fig. 2.2B). 
Maximal secretion as a percentage of the total insulin content was similar under both 
conditions, plateauing near 15 mM glucose.  
Human β-cells exhibited a similar response to chronic culture in excess nutrients. 
72-hour culture in excess oleate/palmitate reduced insulin content by approximately 50% 
regardless of the glucose concentration (Fig. S1.2A). Cells cultured in 11 mM glucose 
with oleate/palmitate showed increased basal secretion and no difference in maximal 
secretion compared to cells cultured in 5.5 mM glucose when expressed as a percent of 
content secreted (Fig. S1.2). Cells cultured in 11 mM glucose or oleate/palmitate 
appeared to have a moderately left-shifted dose-response curve for GSIS, though this was 
difficult to quantitate because of the low fold secretion and lack of sigmoidicity. This 
may be due to the predominance of GLUT-1 over GLUT-2 in human islets compared to 
rodent islets (McCulloch et al., 2011). 
Culture media glucose concentration affected intracellular lipid, insulin content and the 
concentration dependence of GSIS in INS-1 cells 
In order to determine the underlying cause of the observed left-shifted GSIS, we 
used the clonal β-cell line INS-1 (832/13), which retain many of the characteristics of 
normal β-cells (Hohmeier et al., 2000). INS-1 cells are traditionally cultured in high (11 
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mM) glucose, which has been reported to increase intracellular lipid (Roche et al., 1998). 
In an attempt to reduce the intracellular lipid in these cells, we lowered the glucose to a 
more physiological concentration of 4 mM glucose. Chronic culture in 11 mM glucose 
(11G cells) resulted in approximately five times more intracellular lipid compared to cells 
chronically grown in 4 mM glucose (4G cells) (Fig. 3.2A, B). This was confirmed using 
an enzymatic measurement to determine amounts of intracellular TAG (Fig. S2.2) 11G 
cells had about one-third the total insulin stores as 4G cells (Fig. 3.2C), consistent with 
the reduction found in islets cultured with 0.2 mM oleate. We next tested the dose-
response curve for GSIS (Fig. 3.2D). No significant difference was observed in insulin 
secretion at 1 and 2 mM glucose. Stimulated insulin secretion was observed at 3 mM 
glucose in 11G cells while 4G cells did not respond until 5 mM glucose. Despite 
differences in sensitivity to low glucose concentrations, 4G and 11G cells both reached 
maximal GSIS at approximately 8 mM glucose. 4G cells exhibited significantly increased 
maximal secretion compared to 11G cells whether expressed as an absolute amount of 
insulin secreted (data not shown) or as a percent content secreted (Fig. 3.2D).  
Best-fit curves of individual experiments were used to calculate the glucose 
concentration at which 10%, 25% and 50% of maximal secretion occurred (subsequently 
referred to as the S0.1, S0.25 and S0.5 respectively) in order to assess glucose sensitivity. 
This analysis statistically confirmed the left shift in 11G cells suggested by Figure 3.2D, 
as demonstrated by a reduced S0.1, S0.25, and S0.5 compared to 4G cells (Table 1). The 
largest disparity was in the S0.1, which was 4.9 and 2.6 mM glucose in 4G and 11G cells 
 	42	
respectively. This reflected the very different glucose thresholds required for stimulated 
secretion between cells cultured under these two conditions. 
Switching 11G cells to 4 mM glucose resulted in a right-shift in the concentration 
dependence of GSIS within 48 hours (Fig. 4.2A). An increased S0.1, S0.25 and S0.5 
compared to 11G cells corroborated this notion with only the S0.1 being significantly 
different from cells chronically cultured in 4 mM glucose (p<0.05, Table 1).  
Alteration of the glucose dose-response by addition of oleate to INS-1 cells cultured at 4 
and 11 mM glucose 
From the previous experiments it was clear that 11G cells had more intracellular 
lipid and a left-shifted concentration dependence of GSIS compared to 4G cells. To 
determine whether the left shift was driven by, or simply associated with, the ability of 
high glucose to increase intracellular lipid, we supplemented the culture media of 4G and 
11G cells with the common monounsaturated LC FA oleate. Culture of 4G cells with 
0.15 mM oleate for 24 hours increased lipid accumulation approximately 3.5 fold and 
decreased the total insulin content by one-third (Table 1). The concentration dependence 
of GSIS was left shifted compared to the 4G cells, consistent with the hypothesis that 
something closely associated with, or derived from accumulated lipid influenced the 
concentration dependence of GSIS. A lowering of the threshold needed for stimulatory 
secretion from 5 mM glucose to 3 mM was observed without any significant differences 
in maximal secretion (Fig. 4.2B). This resulted in a marked reduction of the S0.1 in 4G 
cells supplemented with oleate to a value similar to that observed in 11G cells. The S0.25 
and S0.5 were also decreased, though the latter was not statistically significant (Table 1).  
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Culture of 11G cells with 0.15 mM oleate for 48 hours resulted in increased lipid 
accumulation without having any significant effect on the total insulin content (Table 1). 
A significant increase in secretion at 1 and 2 mM glucose and reduction in maximal 
insulin secretion was documented when 11G cells were supplemented with oleate (Fig. 
4.2C). This resulted in a decrease in the S0.1, S0.25 and S0.5 in 11G cells cultured in oleate 
compared to 11G cells (Table 1). Importantly, the reduction in maximal insulin secretion 
does not affect the indices of glucose sensitivity. 
A clear inverse relationship existed between the amount of intracellular lipid and 
the S0.25 of the insulin secretion glucose dose-response (Fig. 4.2D). Taken together, these 
results document the ability of excess nutrient cultures to induce glucose hypersensitivity 
in INS-1 cells, a phenomenon that appears to be closely tied to increased intracellular 
lipid.  
The T2D drug Metformin is known to activate AMPK and increase FA oxidation 
by inhibiting ACC (Prentki et al., 2002). Culture of 11G cells with 0.5 mM metformin for 
48 hours reduced intracellular lipid stores (Fig. S3.2A). Interestingly, similar to switching 
11G cells to 4G for 48 hours, incubation with 0.5 mM oleate increased insulin content 
and right-shifted the dose-response curve for GSIS (Fig S3.2B, C).  
No difference in GK activity in 4G and 11G cells 
 Evidence exists to suggest that the glucose-sensing enzyme GK plays an 
important role in controlling glucose flux in β-cells (German, 1993). We therefore wanted 
to determine whether differences in GK activity existed between 4G and 11G cells, which 
are right and left shifted relative to one another. We used an in vitro GK activity assay in 
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which incremental increases in glucose are coupled to production of NADPH. No 
significant differences were detected at any of the glucose concentrations tested, 
including those in the range of hexokinase I (0.01-1 mM) (Fig. 5.2). 
 Because the previous assay removes possible regulatory, thiol (DTT is used in the 
assay) or localization modifications to GK, we verified the previous result with an intact-
cell measurement of GK activity. The intact-cell method distinctly allowed for 
assessment of possible differences in glucose transport and phosphorylation capacity. To 
achieve this, we monitored glucose uptake over a range of relevant concentrations using a 
fluorescently tagged, non-metabolizable glucose analog, 2-NBDG. Again, no differences 
were observed in glucose uptake or phosphorylation at any concentration tested, 
suggesting that altered glucose flux did not contribute to the left shift observed in INS-1 
cells cultured chronically at high glucose (Fig. S4.2).  
 Metabolic changes in response to acute glucose in β-cells cultured in different nutrient 
environments 
 Culture of INS-1 cells in high glucose has been reported to increase mRNA and 
protein levels of key glycolytic regulatory enzymes apart from GK including 
phosphofructokinase-1, glyceraldehyde 3-phosphate dehydrogenase and pyruvate kinase 
(Roche et al., 1997). To assess whether alterations in glucose metabolism distal to GK 
could account for the left shift, we assessed changes in NAD(P)H concentration (by 
autofluoresence) and respiration in response to relevant concentrations of glucose. We 
determined that both 4G and 11G cells were approximately 10% reduced at 2 mM 
glucose (Fig. 6.2A). Both 4G and 11G cells exhibited a similar increase in NAD(P)H 
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autofluoresence upon a rise of the extracellular glucose concentration from 2 to 4 mM. A 
further increase was observed when the glucose concentration was raised to 6, 8 and 12 
mM glucose (Fig. 6.2A). At these glucose concentrations, a small increase in NAD(P)H 
as a percent of the full-scale was seen in 11G cells compared to 4G cells, though only the 
difference at 12 mM glucose was significant (p<0.01).  
A similar procedure was performed to examine NAD(P)H concentration in 
response to relevant glucose concentrations in whole islets incubated with and without 
oleate. Upon an increase of the glucose from basal to 5 and 7 mM glucose, both islets 
cultured with and without oleate exhibited a similar increase in fluorescence (Fig. 6.2B). 
In response to 11 and 15 mM glucose, islets cultured in oleate had a tendency to become 
more reduced than islets not cultured in oleate (p=0.07, 0.06 for 11, 15 mM glucose, 
respectively) (Fig. 6.2B).  
We further examined these effects by gauging changes in the oxygen 
consumption rate in response to the same glucose concentrations used to assess redox. 
Oxygen consumption at 2 mM glucose was significantly higher in 11G cells (1535 ± 141 
pmol/106 cells/min) compared to 4G cells (1091 ± 91 pmol/106 cells/min) (n=4, p<0.05). 
Following a 32-minute baseline, the extracellular glucose was raised to 4, 6 or 8 mM 
glucose. The responses to each glucose concentration as a percent increase over basal (2 
mM glucose) respiration were similar in both 4G and 11G cells (Fig. 7.2A). However, 
when compared on an absolute basis, 11G cells consumed more oxygen at 4 (Fig. 7.2B), 
6 (Fig. 7.2C), and 8 mM glucose (Fig. 7.2D). Thus, at any given glucose concentration, 
increased rates of respiration were observed in 11G cells compared to 4G cells. However, 
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this difference was primarily due to an increase in basal respiration rather than a shift in 
the glucose dose-response. 
Following 60 minutes at 4, 6, and 8 mM glucose, mitochondrial function was 
assessed. Injection of oligomycin, an ATP-synthase inhibitor, indicated that more 
respiration was coupled to ATP synthesis in 11G cells at all glucose concentrations 
except 8 mM (Fig. 7.2E). Inhibition of all electron flow with antimycin A resulted in 
minimal respiration, which was identical in both 4G and 11G cells. The mitochondrial 
leak, defined as proton flow back across the inner mitochondrial membrane not coupled 
to ATP synthesis (oligomycin insensitive), was increased in INS-1 cells cultured at high 
glucose, which has been previously observed (Fig. 7.2F) (Gohring et al., 2014). The 
increased leak accounted for approximately half of the elevated basal respiration in 11G 
cells. The other half is likely a result of increased FA oxidation, mitochondrial mass or a 
combination thereof. Maximal respiration following injection of the uncoupler FCCP was 
greater in 11G cells at every glucose concentration. This increase in maximal respiration 
indicated that mitochondrial mass was likely increased in 11G cells and contributed to the 
elevated basal respiration. 
No significant differences in [Ca2+]i in β-cells with high or low intracellular lipid 
The absence of a left-shift in redox and respiration linked to ATP synthesis 
prompted us to look at [Ca2+]i in response to the same glucose concentrations. 
Additionally, a modification at the KATP channel or VDCC could alter Ca2+ influx 
independent of altered metabolism and account for the left shift. We used the Ca2+ dye 
fura-2 to determine the changes in [Ca2+]i in response to a rise in the extracellular glucose 
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concentration. Interestingly, our results show that when the extracellular glucose was 
raised from 2 to 4 mM, a substantial increase in [Ca2+]i occurred in both 4G and 11G cells 
(Fig. 8.2A, B). A similar increase in average Ca2+ was observed in response to 8 mM 
glucose (Fig. 8.2C, D).  
 We found a similar result in islets cultured with and without oleate. Average 
[Ca2+]i increased in response to 7 mM glucose in both groups (Fig. 9.2A, B). Islets 
cultured with oleate displayed less of a lag in the Ca2+ rise upon an increase of the 
glucose to 7 mM. There was no significant rise in [Ca2+]i when the glucose concentration 
was raised from 7 to 15 mM in either islet type (Fig. 9.2A, B). This is consistent with 
previous reports which have suggested a discordance between the [Ca2+]i and insulin 
secretion in the context of a glucose dose-response (Antunes et al., 2000; Heart et al., 
2006; Henquin et al., 2006). The majority of control islets (20/31, 65%) demonstrated 
Ca2+ oscillations with a period of approximately 3 minutes (179.7 ± 16.6 seconds, Fig. 
9.2C) as previously shown (Heart et al., 2006). None of 26 separate islets cultured with 
oleate displayed [Ca2+]i oscillations in response to glucose (Fig. 9.2D).  
 Taken together, these data indicate that differences in either the glucose 
concentration at which Ca2+ influx occurs or the amount of Ca2+ influx is unlikely to 
drive the left-shifted insulin secretion in β-cells with elevated intracellular lipid. 
Concentration dependence of lipolysis induced by glucose in 4G and 11G cells 
Elevated glucose is known to increases lipolysis in β-cells (Winzell et al., 2006). 
Glycerol release can be used as a measure of lipolysis rates in β-cells because β-cells do 
not express glycerol kinase (Nolan et al., 2006b). Both 11G cells and cells cultured in 4 
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mM glucose for 48 hours exhibited enhanced lipolysis in response to an acute elevation 
of the glucose concentration from basal to high glucose (Fig. S.5.2). However, only 11G 
cells exhibited increased glycerol release at intermediate glucose concentrations (4 mM). 
Concentration dependence of amplification of insulin secretion by glucose in 4G and 11G 
cells 
While the exact mechanisms by which glucose amplifies insulin secretion remain 
unclear, it may in part have to do with its ability to enhance lipolysis and FA cycling 
(Nolan et al., 2006b). Enhanced amplification at submaximal glucose concentrations 
could theoretically account for the left shift in β-cells cultured in excess nutrients. This 
was a particularly attractive explanation due to the clear relationship between lipid stores 
and the S0.25 of GSIS.   
 To test this, we assessed insulin secretion in both 4G and 11G cells at relevant 
glucose concentrations while in the presence of 30 mM KCl and 0.4 mM DZ. This 
maneuver causes [Ca2+]i to be clamped at an elevated concentration independent of KATP 
channel closure by ATP (Henquin, 2000). As a result, basal insulin secretion was greatly 
increased (Fig. 10.2 compared to 3.1D). No differences in amplification were detected. A 
glucose dose response was observed in both 4G and 11G cells, with no significant 
differences at any glucose concentration tested, in contrast to previous results obtained 
under normal conditions (Fig. 3.2D). The stimulation of insulin secretion by 4 mM 
glucose in 4G cells under KCl/DZ conditions indicates that these cells are capable of 
responding to low glucose concentrations if the Ca2+ is elevated high enough. 
 	49	
Sensitivity of exocytosis to Ca2+ in 4G and 11G cells 
The lack of insulin secretion above basal in response to acute exposure of 4 mM 
glucose in 4G cells despite a clear rise in [Ca2+]i suggested the possibility of a change in 
Ca2+ sensitivity of exocytosis. We utilized a permeablized cell system to test this directly 
in which the free Ca2+ was set to the desired concentration by varying the Ca2+/EGTA 
ratio. Nutrients were omitted from the buffer and instead an ATP regenerating system 
was used, reducing potential confounding differences in metabolism. Similar to GSIS, we 
found that 11G cells had a left-shifted dose-response curve for Ca2+ induced exocytosis 
compared to 4G cells (Fig. 11.2). The S0.5 and S0.25 were both reduced by approximately 
30% in 11G cells compared to 4G cells. Interestingly, the S0.5 in 11G cells (1.8 µM) was 
comparable to the S0.25 in the 4G cells (1.7 µM), which was also the case in the glucose 
dose-response curves (Table 1).  
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DISCUSSION 
 The work presented here provides compelling evidence to suggest that β-cells 
cultured in excess nutrients exhibit hypersensitivity to acute stimulation with submaximal 
glucose concentrations. This hypersensitivity resulted in a left-shifted concentration 
dependence of GSIS. These data indicated that a shift in the dose-response curve for 
GSIS may contribute to the hypersecretion of insulin observed in obesity. The shift was 
not driven by heightened glucose flux into the β-cell or alterations in the consensus 
pathway by which glucose stimulates insulin secretion. Rather, it appeared that a shift in 
the sensitivity of exocytosis to Ca2+ was at least in part responsible for the left-shift in the 
dose response for GSIS following exposure to excess nutrients. 
 The effect of FAs on β-cell function has been well studied and is clearly a matter 
of exposure time, concentration, chain length and saturation level. Acutely, FAs 
potentiate GSIS, with LC saturated FAs being the most potent (Stein et al., 1997). 
Conversely, chronic incubation in FA inhibits GSIS, both in vitro and in vivo, especially 
when combined with elevated glucose (Olofsson et al., 2007; Paolisso et al., 1995). Our 
data highlight the importance of accounting for the altered insulin content when 
determining and interpreting the functional capacity of the β-cell to secrete insulin in 
vitro. Under GLT, preservation of, or normalization to, insulin content resulted in a 
different interpretation of the secretory capacity of islets. Instead of reduced secretion, the 
islets actually displayed enhanced secretion at both basal and intermediate glucose 
concentrations, and had unaltered maximal secretion, indicating a left-shift in GSIS. 
Thus, displaying insulin secretion both as an absolute amount and normalizing to insulin 
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content can help to identify alterations in insulin synthesis/stores versus secretion. Under 
high lipid conditions, there is a clear defect in insulin synthesis/stores that masks the fact 
that the capacity of the β-cell to secrete insulin is actually enhanced. Loss of insulin 
content could be a precursor to β-cell failure, but when coupled to hypersecretion may 
result in only mild HI. Further research is needed to clarify this distinction and to 
determine the relationship between insulin content and secretion in vivo. Interestingly, a 
previous study showed that DZ administration during sustained glucose infusion 
preserved insulin content and enhanced GSIS from isolated islets ex vivo (Sako and Grill, 
1990). 
We have developed a model to study this shift through chronic culture of INS-1 cells 
at physiological and high glucose concentrations. While it is known that clonal β-cells 
have a left-shifted dose-response curve for GSIS compared to islets, the underlying cause 
of this is not known. Given reports that have documented glucose to be a key regulator of 
lipogenesis in INS-1 cells, we decided to reduce the culture glucose to a more 
physiological concentration to try to ‘normalize’ these cells to better resemble islets 
(Roche et al., 1998). Chronic culture at 4 mM glucose caused a dramatic reduction in 
intracellular lipid stores compared to cells cultured at 11 mM glucose. This reduction in 
lipid stores was associated with a right-shifted dose-response curve for GSIS. In addition 
to its effect on lipid stores, chronic exposure to elevated glucose has also been shown to 
change the expression of many genes in insulin secreting cell lines, thus making it 
difficult to implicate lipid in the initiation of the left shift using this model alone (Schuit 
et al., 2002). To resolve this, we added oleate overnight to INS-1 cells cultured at 
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physiological glucose. We obtained a similar left-shift in the concentration dependence of 
GSIS when compared to chronic culture at high glucose. This increases the likelihood 
that lipid was indeed playing a causative role in the left shift induced by chronic 
incubation in high glucose.  
Chronic culture of islets and INS-1 cells in very high glucose (>25 mM) has been 
shown to induce a similar shift in the concentration dependence of GSIS (Ling et al., 
1996; Roche et al., 1997). Studies have implicated an increase in glycolytic flux resulting 
from enhanced expression of key glycolytic enzymes as the underlying cause (Roche et 
al., 1997). This phenomenon has also been observed in vivo in humans following chronic 
glucose infusion to invoke sustained hyperglycemia (Byrne et al., 1995). Interestingly, 
this same study showed that fasting induces a right-shift in GSIS. Our results build upon 
these studies by also demonstrating that chronic exposure of β-cells to high glucose alters 
the dose-response curve for GSIS and implicates lipid accumulation as playing a major 
role 
 While a clear inverse relationship exists between the S0.25 of GSIS and lipid stores 
in INS-1 cells, it is unlikely that an inert molecule like triglyceride would be driving this 
shift in GSIS. To more thoroughly investigate the underlying cause of this shift, we 
examined the known pathways by which glucose stimulates insulin secretion. GK activity 
was not different between 4G and 11G cells. In response to acute stimulation with 4 mM 
glucose, both 4G and 11G cells exhibited increased NADH, oxygen consumption and 
[Ca2+]i. We also found no significant differences in the [Ca2+]i in response to intermediate 
glucose. Interestingly, only 11G cells exhibited triggering of insulin secretion in response 
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to this Ca2+ influx. 4G cells did not exhibit triggering until the glucose was further raised 
despite no additional increase in [Ca2+]i. We demonstrated that β-cells with high 
intracellular lipid have an increased sensitivity of exocytosis to Ca2+, narrowing the 
possible sites responsible for the left shift to the exocytotic machinery or the plasma 
membrane. Because glycerol release was only elevated above basal at intermediate 
glucose concentrations in left-shifted INS-1 cells, it is possible that a signal generated 
from lipolysis is necessary for triggering. Modification to the putative exocytotic Ca2+ 
sensor synaptotagmin is a likely target. Interestingly, studies have shown that proteins 
within the exocytotic machinery including synaptotagmin and SNAP25 are acylated 
(Greaves et al., 2010; Heindel et al., 2003). We have previously shown that LC-CoA 
enhances secretory granule exocytosis in β-cells, an effect that was blocked by cerulenin, 
which inhibits protein acylation (Deeney et al., 2000). Another likely lipid candidate is 
MAG. We have recently shown that MAG stimulates basal insulin secretion and Zhao et 
al. have shown that it binds the exocytotic protein Munc13-1 (Saadeh et al., 2012; Zhao 
et al., 2014). Another possibility is that a change in the lipid composition of the plasma 
membrane may alter the Ca2+ threshold needed for GSIS and thus shift the dose-response 
curve. Cholesterol and phosphotidylserine are two important membrane components that 
have been shown to affect exocytosis in multiple cell types (Lai et al., 2011; Rituper et 
al., 2012). 
 In summary, we have demonstrated that INS-1 cells and rat islets with high 
intracellular lipid display a hypersensitivity to acute glucose stimulation. Such conditions 
lower the S0.25 and left-shift the concentration dependence of GSIS. The mechanism 
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underlying this shift appears to emanate from a heightened sensitivity of the Ca2+ induced 
triggering pathway directly at the exocytotic machinery. The strong relationship between 
lipid stores and hypersecretion of insulin at submaximal glucose suggest the need for 
further investigation into the possible role of such lipid species as LC-CoA, cholesterol 
and MAG among others. Studies on these pathways are currently underway in our 
laboratory.  
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Figure 1.2. Preserving insulin content during culture in high lipid concentration 
increases insulin secretion at basal and intermediate glucose in isolated rat islets.  
 
Islets were cultured in standard culture media (11 mM glucose) with or without 0.2 mM 
oleate plus or minus 0.4 mM DZ for 48 hours. (A) Insulin content following exposure to 
these conditions. (B) Islets were perifused at basal (3 mM) glucose for 30 minutes and a 
baseline was collected for 10.5 minutes. Islets were stimulated with 11 mM glucose and 
then brought to 15 mM glucose at 34 minutes. Lines are a 2-point running average fit to 
data points. Error bars are displayed every sixth point for clarity. (C) The same insulin 
secretion as in (B) but expressed as a percentage of total insulin content secreted. (D) 
Fold stimulation over basal insulin secretion by 11 mM glucose derived from (B). Basal 
insulin secretion was the average of 0-12.6 min and stimulated secretion was the average 
of 16.1-17.2 min. Data are derived from 3 independent experiments ± S.E.M. (*, p<0.05; 
+, p<0.001). Colors from A correspond to B, C, D. 
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Figure 2.2. Rat islets cultured in a high lipid environment exhibit a left-shifted 
concentration dependence of GSIS.  
Whole islets from the same rat were incubated in standard culture media (11 mM 
glucose) with or without 0.1 mM oleate. Following a 48-hour incubation, the (A) total 
insulin content and (B) concentration dependence of GSIS was assessed. Each 
experiment was normalized to its own content. The S0.25 was derived from the mean 
dose-response curve of all experiments. Data comprised of 11 separate experiments ± 
S.E.M. from independent isolations, (*, p<0.05). 
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Figure 3.2. Reduction of culture glucose decreases lipid stores, increases insulin 
content and right-shifts the dose-response curve of GSIS in INS-1 cells.  
Lipid stores were assessed with the dye Nile red and representative images taken at 20X 
magnification are shown for (A) 11G and (B) 4G cells. The (C) total insulin content and 
(D) acute insulin secretion response to a range of glucose concentrations in 4G and 11G 
cells. Insulin secretion was normalized to the total insulin content and expressed as a 
percentage of total content secreted. Data are means ± S.E.M from 12 and 13 independent 
experiments for 4G and 11G cells, respectively (n = 3-4 replicates for each point in a 
given experiment). A two-tailed Student’s t test was used for comparisons between 
conditions (*, p<0.05; #, p<0.01; +, p<0.001). 
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Figure 4.2. INS-1 cells cultured in excess nutrients have a left-shifted insulin 
secretion glucose-dose response.  
(A) Transition of 11G cells to 4 mM glucose for 48 hours. (B) Supplementation of 4G 
cells with 0.15 mM oleate (FA) for 24 hours. (C) Incubation of 11G cells with 0.15 mM 
FA for 48 hours (8, 6 and 4 independent experiments for 4G (48 hr), 4G FA and 11G FA, 
respectively). (D) Correlation analysis between intracellular lipid and the quarter-
saturation level for GSIS derived from Table 1 (u, 4G cells; u, 4 mM glucose for 48 
hours; u, 4G cells with 0.15 mM oleate; n, 11G cells; n, 11G cells with 0.15 mM 
oleate). Data expressed as mean ± S.E.M., (*, p<0.05; #, p<0.01; +, p<0.001). 
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Figure 5.2. Chronic culture in high glucose does not affect GK activity in INS-1 
cells.  
GK activity was determined by the rate of NADPH appearance as described in the 
methods. The slope of NADPH fluorescence was determined at different glucose 
concentrations and was normalized to the protein content of the soluble portion of the 
extract (n = 6 independent experiments). Data are presented as mean ± S.E.M. with no 
significant differences detected between 4G and 11G cells as determined by one-way 
ANOVA.  
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Figure 6.2. No difference in NAD(P)H concentration in β-cells with left- and right-
shifted GSIS.  
(A) The autofluorescence of NAD(P)H was assessed in 4G (Cholesterol Treatment 
Trialists et al.) and 11G (Laybutt et al.) cells both basally (2 mM glucose) and in response 
to glucose stimulation at 4, 6, 8 and 12 mM glucose. (B) NAD(P)H production in 
response to glucose was assessed in whole isolated pancreatic islets cultured in 0 mM 
oleate (Cholesterol Treatment Trialists et al.) and 0.1 mM oleate (Laybutt et al.). Islets 
were brought from basal (3 mM glucose) to the concentrations indicated. NAD(P)H is 
expressed as a percent of the full scale as described in methods. N = 6-7 and 6 separate 
experiments for (A) and (B) respectively. Each experiment consisted of 4-6 islets per 
condition in (B). Data are presented as mean ± S.E.M., one-way ANOVA used for 
comparisons between conditions (#, p<0.01). 
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Figure 7.2. Increased mitochondrial leak in 11G cells but no change in the glucose 
dose response of O2 consumption.  
(A) Increase in oxygen consumption as a percent increase over basal in 4G (Cholesterol 
Treatment Trialists et al.) and 11G (Laybutt et al.) cells. Oxygen consumption traces 
documenting the differences between 4G (u) and 11G (u) in response to acute 
stimulation with (B) 4 mM, (C) 6 mM and (D) 8 mM glucose. (E) Oligomycin sensitive 
respiration used to estimate ATP synthesis (F) Oligomycin insensitive respiration used to 
estimate mitochondrial leak. Figures are averages from four separate experiments ± 
S.E.M (n = 4 replicates per experiment), (*, p<0.05). 
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Figure 8.2. Increase in [Ca2+]i at 4 mM glucose in both 4G and 11G cells.  
(A) 4G and (B) 11G cells were brought from 2 mM glucose to 4 mM glucose at 4 
minutes and the change in average [Ca2+]i was documented. The same procedure was 
carried out in response to 8 mM glucose in (C) 4G and (D) 11G cells. Experiments 
consisted of ~150 cells per trace. Data are expressed as the mean ± S.E.M. from four 
independent experiments. Error bars are shown every tenth reading for clarity.  
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Figure 9.2. Decreased lag time but no change in [Ca2+]i glucose dose response in 
whole islets cultured with oleate.  
Whole islets were brought from a baseline of 3 mM glucose to 7 mM glucose at 3 
minutes and then to 15 mM glucose at 15 minutes. Average response from (A) control 
islets (31 from 5 rats) cultured without oleate and (B) islets cultured for 48 hours with 0.1 
mM oleate (26 from 5 rats). Error bars are shown every tenth measurement for clarity. A 
3-point running average of a representative islet from (C) control culture and (D) 0.1 mM 
oleate culture.  
 
 
 
 
 
 
 
 
 	64	
 
Figure 10.2. No change in amplification of insulin secretion by glucose in 4G and 
11G cells.  
Data are presented as mean ± S.E.M. from 3 independent experiments (n = 3-4 wells per 
glucose concentration), no significant differences detected by a one-way ANOVA. 
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Figure 11.2. 11G cells have a left-shifted sensitivity of exocytosis to Ca2+.  
Cells were permeabilized and exposed to different Ca2+ concentrations in the presence of 
an ATP regenerating system. Each curve is a mean of 4 independent experiments ± 
S.E.M. (n = 3-4 wells per condition). The S0.25 and S0.5 values were derived from the 
mean of values obtained from each individual experiment ± S.E.M. A two-tailed 
Student’s t test was used for comparisons between conditions (*, p<0.05; #, p<0.01; +, 
p<0.001) 
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Figure S1.2. Insulin content and secretion from human pancreatic islet cells 
cultured in different nutrient conditions.  
Insulin secretion was measured following 4 days in either 5.5mM glucose with BSA, 
11mM glucose with BSA, 5.5mM glucose w/ oleate/palmitate complexed to BSA, or 
11mM glucose with oleate and palmitate complexed to BSA. Incubations were started as 
whole islets for 48 hours and subsequently dispersed and reaggregated. Following 48 
hours for reaggregation insulin secretion was performed in a KREBS buffer (45 min 
preincubation at 3mM glucose, 1 hour secretion at given glucose concentrations). 
Secretion was expressed as a percentage of the total content. Data is an average of 
secretion from reaggregated islets of 3 separate donors. 
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Figure S2.2. Triglyceride content from INS-1 cells cultured in various nutrient 
environments.  
Data are presented as mean ± S.E.M. from 3 independent experiments (n = 3 wells per 
condition per experiment.) 
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Figure S3.2. Metformin decreased intracellular lipid and right shifted the dose-
response curve for GSIS.  
(A) Nile red images from INS-1 cells incubated in 11 mM glucose with or without 0.5 
mM Metformin for 48 hours.  (B) Insulin content and (C) secretion from INS-1 cells 
incubated in Metformin. Secretion data represent 1 experiment with 4 samples per 
glucose concentration. 
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Figure S4.2. No difference in glucose uptake between 4G and 11G cells.  
Uptake of 2-NBDG was monitored in 4G (n) and 11G (n) cells at relevant glucose 
concentrations. Individual experiments were normalized to the uptake at 2 mM glucose in 
4G cells from 4 experiments (n = 4 for independent experiments). Data presented as 
mean ± S.E.M., no significant differences detected between 4G and 11G cells as 
determined by one-way ANOVA.  
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Figure S5.2. Increased glycerol release at 4 mM glucose in 11G cells compared to 4G 
cells.  
Data are presented as mean ± S.E.M. from 3 independent experiments (n = 3-4 wells per 
glucose concentration). 
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Table 1. Effect of chronic culture of INS-1 cells in different nutrient environments 
on insulin content, lipid accumulation and glucose sensitivity.  
Data are mean ± S.E.M. from 12, 8, 6, 13, 4 independent experiments for 4G, 4G (48 hr), 
4G FA, 11G and 11G FA respectively. A two-tailed Student’s t test was used to compare 
data to 4G cells.  
 
4G 4G (48 hrs) p 4G, 0.15 mM FA (24 hrs) p 11G p 
11G, 0.15 mM FA 
(48 hrs) p 
Insulin content 
(ng/106 cells) 898 ± 155 1159 ± 274 N.S. 576 ± 169 <0.05 307 ± 37 <0.001 293 ± 27 <0.05 
Lipid  
(% cell area) 2.0 ± .4 2.7 ± .6 N.S. 6.7 ± 1.3 <0.001 9.2 ± .9 <0.001 12.5 ± 1.5 <0.001 
S0.1 4.9 ± .2 3.8 ± .3 <0.05 2.9 ± .3 <0.001 2.6 ± .2 <0.001 1.8 ± .1 <0.001 
S0.25 5.7 ± .2 5.1 ± .2 N.S. 4.5 ± .2 <0.001 3.5 ± .3 <0.001 2.4 ± .1 <0.001 
S0.5 6.7 ± .2 6.3 ± .3 N.S. 6.0 ± .4 N.S. 5.0 ± .2 <0.001 4.0 ± .3 <0.001 
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ABSTRACT 
Lipid signals derived from lipolysis and membrane phospholipids play an important role 
in GSIS, though the exact secondary signals remain unclear. Previous reports have 
documented a stimulatory role of exogenously added MAG on insulin secretion from 
cultured β-cells and islets. In this report we have determined effects of increasing 
intracellular MAG in the β-cell by inhibiting MGL activity, which catalyzes the final step 
in TAG breakdown, namely the hydrolysis of MAG to glycerol and FFA. To determine 
the role of MGL in GSIS, we used three different pharmacological agents (JZL184, 
MJN110 and URB602). All three inhibited GSIS and depolarization-induced insulin 
secretion in INS-1 (832/13). JZL184 significantly inhibited both GSIS and 
depolarization-induced insulin secretion in rat islets. JZL184 significantly decreased 
lipolysis and increased both mono- and diacyglycerol species in INS-1 cells. Analysis of 
the kinetics of GSIS showed that inhibition was greater during the sustained phase of 
secretion. A similar pattern was observed in the response of Ca2+ to glucose and 
depolarization but to a lesser degree suggesting that altered Ca2+ handling alone could not 
explain the reduction in insulin secretion. In addition, a significant reduction in long 
chain-CoA (LC-CoA) was observed in INS-1 cells at both basal and stimulatory glucose 
following inhibition of MGL. Our data implicate an important role for MGL in insulin 
secretion.  
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INTRODUCTION 
Decades of research have demonstrated a critical role for IR in the manifestation 
of T2D. However, a decline in β-cell function characterized by an inability to adequately 
respond to an acute glucose challenge, clearly distinguishes those who go on to develop 
for T2D from those who can maintain glucose homeostasis (Halban et al., 2014). Our 
understanding of what causes β-cell failure is unclear, and may involve a multitude of 
factors including a decrease in β-cell mass, dedifferentiation of β-cells and apoptosis 
caused by exposure to excess nutrients (Halban et al., 2014). Additionally, chronic 
exposure to elevated glucose and FA has been shown to cause increased basal and 
reduced GSIS, though the precise mediators of this effect remain unclear (Bollheimer et 
al., 1998; Erion et al., 2015; Olofsson et al., 2007; Oprescu et al., 2007). 
The consensus mechanism by which glucose stimulates insulin secretion involves 
a rise in [Ca2+]i  that promotes the ‘triggering’ of insulin granule fusion with the plasma 
membrane via SNARE proteins (Wang and Thurmond, 2009). Additional pathways and 
processes derived from glucose metabolism amplifies the insulin secretion induced by 
triggering (Henquin, 2011). Part of the amplification pathway of GSIS involves GL/FFA 
cycling wherein glucose provides the glycerol backbone for FA esterification via 
α-glycerophosphate and also promotes lipolysis from lipid stores (Prentki and Madiraju, 
2012). This GL/FFA cycle provides important signaling molecules, including LC-CoA, 
MAG and DAG (Prentki and Madiraju, 2012). The targets of these lipid signals are 
diverse, including the stimulation of proteins involved in exocytosis (Brown et al., 1998; 
Brown et al., 2000; Deeney et al., 2000; Deeney et al., 1992; Larsson et al., 1996; 
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Olszewski et al., 1994; Yaney et al., 2002), to broad kinases including PKC and ion 
channels (Deeney et al., 2000). 
While the role of DAG in GSIS has been studied extensively, the role of MAG 
has only recently garnered interest. We previously documented that acute treatment with 
mono-oleoyl-glycerol increases both basal and GSIS. Increased basal secretion depended 
on ROS (Saadeh et al., 2012). The Prentki group recently demonstrated the importance of 
the plasma membrane MAG lipase ABHD6 as a regulator of GSIS (Zhao et al., 2014).  
Inhibition of this enzyme enhances insulin secretion at stimulatory glucose by increasing 
local MAG concentration and activating the exocytotic protein Munc-13a, which can 
bind both MAG and DAG. MGL, like ABHD6, is a serine hydrolase that removes the 
final FA during the breakdown of TAG to generate glycerol and FFA (Labar et al., 2010). 
Research on this enzyme has focused on regulation of 2-arachidonoylglycerol synthesis 
in the brain, though it is known that the enzyme displays broad tissue distribution 
(Blankman et al., 2007; Mulvihill and Nomura, 2013). Unlike ABHD6, MGL has been 
reported to be located in both plasma membrane and cytosol (Labar et al., 2010). The 
contribution of this enzyme to GSIS has not been definitively established.   
Herein, we demonstrate that pharmacological inhibition of MGL dose-
dependently reduced glucose- and KCl-induced insulin secretion in both INS-1 cells and 
isolated rat islets. This reduction primarily occurred in the sustained, or second phase of 
GSIS. This coincided with a significant decrease in the LC-CoA pool and reduction in 
Ca2+ influx in response to both glucose and KCl.  
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MATERIALS AND METHODS 
Ethics Statement − This study was carried out in strict accordance with the 
recommendations in the guide for the care and use of Laboratory Animals and the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee at Boston University Medical Center (Boston University Medical 
Center Animal Welfare Assurance: A-3316-01).  
Islets − Islets were isolated from male Sprague-Dawley rats (150-250 g) as previously 
described (Erion et al., 2015). Briefly, the rat pancreas was excised and minced in 0.5 mL 
of Hank’s balanced salt solution (HBSS) containing 10 mM HEPES and adjusted to pH 
7.4. The minced pancreas was then shaken in 5.5 mL HBSS with 3.3 mg collagenase P 
(1.7 units/mg) (Roche, Indianapolis, IN) in HBSS for 3 minutes at 37oC. The digested 
pancreas was then washed with HBSS supplemented with 0.1% defatted BSA (EMD 
Millipore, Billerica, MA) and further isolated by centrifugation through a Histopaque 
gradient (Sigma, St. Louis, MO). Isolated islets were cultured overnight in RPMI 1640 
(11 mM glucose) without phenol red containing 10% FBS, 5 mM glutamine, 50 IU/mL 
penicillin, 50 µg/mL streptomycin. Islets were dissociated using accutase (Sigma, St. 
Louis, MO). Briefly, approximately 100 islets were incubated with 1 mL accutase at 37oC 
for 10 min and plated at a density of 2000-4000 cells/well in multiwell culture plates 
using matrigel (BD Biosciences, Billerica, MA). 
INS-1 (832/13) Cells − INS-1 (832/13) cells were cultured in RPMI (11 mM glucose) 
with phenol red as above with the addition of 1 mM sodium pyruvate, 10 mM HEPES 
and 50 µM β-mercaptoethanol as previously described (Erion et al., 2015). 
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Insulin Secretion − Insulin secretion was measured from INS-1 cells grown for at least 3 
days to approximately 85% confluence in 48- and 96-well plates as we have described in 
previous work (Saadeh et al., 2012). Briefly, INS-1 cells were preincubated with RPMI 
containing 2 mM glucose without FBS for 2 hours prior to a 30-minute preincubation 
with 2 mM glucose in KREBS at 37oC. The KREBS contained 119 mM NaCl, 4.6 mM 
KCl, 5 mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 
20 mM HEPES, 0.05% BSA, pH 7.4. Dissociated islets and whole rat islets (6 islets/tube) 
were preincubated in 3 mM glucose in KREBS at 37oC for 30 minutes prior to measuring 
secretion. Following preincubations, INS-1 cells and islets were cooled on ice before 
experimental solutions were added. Cells were incubated for 60-120 min at 37oC, cooled, 
and sampled for insulin secretion. Insulin was measured by HTRF insulin assay (CisBio, 
Bedford, MA). Islet perifusions were performed as described previously (Cunningham et 
al., 1996). 
MGL Inhibitor Preparations − JZL184 (Cayman Chemical, Ann Arbor, MI), MJN110 
(Sigma, St. Louis, MO) and URB602 (Cayman Chemical, Ann Arbor, MI) were prepared 
as a DMSO stocks. For experiments stocks were diluted into KREBS or RPMI at 37oC 
while vortexing. The final concentration of DMSO was 0.1% or less. 
Neutral Lipid Quantification − INS-1 cells were grown to 1.2 million cells/well in 12-
well plates. 48 hours before extraction, cells were cultured in RPMI (1 mL/well) 
containing 5 µCi/mL uniformly labeled C14-glucose. Prior to extraction radio-labeled 
cells were incubated as for insulin secretion. Cells were extracted with 3 mL chloroform 
methanol (2:1) and 0.75 mL 168 mM NaCl 0.9 mM HCl. The organic layer was collected 
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and dried under air and separated using single dimension TLC on silica gel G plates using 
hexane:ethyl ether:acetic acid (70:30:1; v/v) as the development system. Individual lipid 
species were located by autoradiography and co-migration with authentic standards. 
Radioactive bands were scraped and radioactivity was quantified using liquid scintillation 
spectrometry. Parallel unlabeled wells were used for normalization by cell count. The 
Bligh-Dyer lipid extraction method was used for the dose-response of MJN110 (Bligh 
and Dyer, 1959). Briefly, cells were treated as for insulin secretion and the plate was 
frozen with liquid nitrogen. Cells were then scraped in PBS and pelleted in 15 mL 
centrifuge tubes. A 2:1 ratio of MeOH:CHCl3 was added to cells, vortexed, and incubated 
overnight at 4°C. A 10:9 ratio of CHCl3:H2O was then added to the tubes which were 
subsequently vortexted and spun at 13,000 RPM for one minute. The CHCl3 phase was 
put into an eppendorf tube and dried under nitrogen gas. After resuspension with 20 µL 
of CHCl3, silica plates were used to spot the CHCl3. After running of the plate it was 
exposed to iodine in a chamber to visualize the lipid bands.  
Glycerol Release − Glycerol was measured enzymatically using glycerokinase and α-
glycerophosphate dehydrogenase from the same final incubation solutions removed from 
INS-1 cells to monitor JZL184-induced insulin release described above. NADH produced 
in the assay was detected by luminescence as previously described (Peyot et al., 2004).  
Ca2+ determination − Intracellular Ca2+ was measured in INS-1 cells and rat islets using 
fura-2 AM (Invitrogen, Carlsbad, CA). INS-1 cells were seeded in 35 mm glass bottom 
dishes (MatTek, Ashland, MA) and cultured as previously described to a density of 
approximately 200,000 cells/well. Cells were then rested in 2 mM glucose RPMI without 
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FBS for 2 hours followed by a 30-minute incubation in 2 mM glucose KREBS with 2 µM 
fura-2 AM and 0.1% pluronic acid (Thermo Fisher Scientific, Waltham, MA). Whole 
islets were loaded with 2 µM fura-2 AM while shaking at 37oC in 3 mM glucose 
KRESBS for 30 minutes. After loading both cells and islets were incubated for 15 
minutes in KREBS without fura-2 AM to complete cleavage of the loaded fura-2 AM 
ester prior to mounting onto the stage of an Olympus DSU spinning disk microscope. A 
stage chamber maintained a 37oC temperature throughout the experiment. Fluorescence 
images were obtained at 20X magnification every 10 seconds with excitation 
wavelengths of 340 and 380 nm and dual emission of 510 nm. 
Whole islets were perifused using a high precision multichannel pump (Ismatec, 
Wertheim, Germany) at a flow rate of 1 mL/min to introduce test solutions. 
Measurements were quantified using ImageJ. For INS-1 cells, test solutions were 
introduced via pipette with concentrated solutions. 16-32 individual INS-1 cells per 
experiments were analyzed using NIS Elements software. Because baseline conditions 
were identical prior to addition of test solutions, all baselines were averaged and 
responses were normalized. 
LC-CoA Measurement − INS-1 cells were grown to 1.2 million cells/well in 12-well 
plates and incubated as for insulin release. Cells were exposed to 10 µM JZL184 for up to 
60 minutes and media sampled for insulin release. Cells were then quick frozen in liquid 
nitrogen and stored at -80oC until processed for LC-CoA analysis. Frozen cells were 
thawed on ice in 1% trichloroacetic acid (TCA) containing 3.75 mM DTT. Cells were 
centrifuged (12,000x g, 3 minutes) and washed 3 times with equal volumes of ether to 
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remove TCA from the precipitate containing LC-CoA. The precipitates were hydrolyzed 
in 3.75 mM K2HPO4 buffer pH 11.5 at 55oC for 10 min to liberate free CoA from the LC-
CoA. Free CoA was then measured enzymatically using the α-ketoglutarate 
dehydrogenase reaction as described previously (Corkey, 1988). Standard curves were 
produced from varying concentrations of both ether washed free CoA and hydrolyzed 
LC-CoA in order to account for recovery during sample processing. NADH produced in 
the assay was then detected by luminescence using NADH-dependent bacterial luciferase 
as detailed by Peyot et al (Peyot et al., 2004). 
Statistical Analysis − Data represent the mean ± standard error. Two-way analysis of 
variance (ANOVA) on log-transformed data was used to assess the main effects of 
glucose (low vs. high) and dose (or time as appropriate) on insulin secretion, with 
repeated measured on the latter (GraphPad Prism 5). When the main effect of dose (or 
time) or interaction between glucose and drug/time on insulin was significant (p < 0.05), 
the effect of drug/time within each glucose concentration was tested by a one-way 
repeated measures ANOVA followed by post-hoc Dunnett’s tests to compare each value 
to the control group. When indicated, paired student’s t-tests were used to determine 
significance of glucose on control. Values of P < 0.05 were considered statistically 
significant.  
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RESULTS 
Inhibition of MGL reduced GSIS 
The effect of pharmacological inhibition of MGL on GSIS was determined using 
JZL184, an MGL inhibitor that acts via carbamoylation of a serine nucleophile (Long et 
al., 2009). Acute stimulation of INS-1 cells with glucose increased insulin secretion by 
approximately 5-fold over a two-hour static incubation period. A marked inhibition was 
seen at 5 µM and maximal inhibition was observed at 10 µM (Fig. 1.3A). JZL184 did not 
significantly affect basal insulin secretion at any concentration tested. Chronic exposure 
of INS-1 cells to JZL184 did not result in any further inhibition of GSIS, and also 
ensured that the decrease was not due to toxicity (Fig. 1.3B). Removal of JZL184 for 2 
hours resulted in a 60% recovery of GSIS, indicating at least partial reversibility (Fig. 
1.3C). 
Since JZL184 has also been shown to inhibit fatty acid amide hydrolase (FAAH), 
albeit at much higher concentrations, we used another inhibitor of MGL, MJN110, which 
reportedly does not inhibit FAAH (Long et al., 2009; Niphakis et al., 2013). Acute 
exposure of INS-1 cells to 10 µM MJN110 resulted in a similar reduction in GSIS 
compared to JZL184 (Fig. 1.3D). Finally, we observed a reduction in GSIS over a two-
hour period using 50 µM URB602, a third MGL inhibitor (Fig. 1.3E) (Hohmann et al., 
2005).   
While INS-1 cells retain many of the characteristics of normal β-cells, the fact 
that they are a tumor cell line necessitates confirmation in primary β-cells. Isolated rat 
islets showed an approximate 35-fold increase in insulin secretion when stimulated with 
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15 mM glucose (Fig. 1.3F). JZL184 at 1 and 10 µM caused an approximately 50 and 75% 
reduction of GSIS, respectively. Perifusion of islets in which the glucose concentration 
was raised from 3 to 15 mM with and without 10 µM JZL184 revealed that inhibition of 
insulin secretion by JZL184 was greater during the sustained phase of GSIS (Fig. 2.3). 
Perifusion with a high concentration of KCl, which depolarizes the plasma membrane 
and increases [Ca2+]i, resulted in a sustained increase in control islets while only a 
transient spike was observed in the islets exposed to JZL184. 
JZL184 inhibits depolarization-induced insulin secretion 
In order to test whether direct depolarization of the plasma membrane could 
recover the defect in GSIS observed with MGL inhibitors, we used a high concentration 
of KCl plus the KATP-channel agonist DZ. Insulin secretion is increased under these 
conditions with or without stimulatory glucose via a sharp peak and mildly elevated 
sustained phase of cytosolic [Ca2+]. Additionally, it is known that glucose can stimulate 
insulin secretion in a concentration dependent manner under these conditions (Sato et al., 
1999). We found that JZL184 completely inhibited KCl/DZ-induced insulin secretion in 
INS-1 cells at both basal and stimulatory glucose (Fig. 3.3A). The MGL inhibitors 
MJN110 and URB602 also inhibited KCl-induced insulin secretion (data not shown). 
Additionally, pharmacological inhibition of MGL completely blocked depolarization-
induced insulin secretion in dissociated islet cells (Fig. 3.3B).  
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JZL184 reduced glycerol release and increased MAGs and DAGs in INS-1 cells 
Glucose stimulates lipolysis from intracellular lipid stores in β-cells (Winzell et 
al., 2006). The sequential hydrolysis of FAs from TAG led to increases in MAGs and 
DAGs. Hydrolysis of MAG generates glycerol, which is released from the cells, and a 
FFA, which can be released or re-esterified (Prentki and Madiraju, 2012). Blocking MGL 
activity with JZL184 should decrease glycerol release from the cell following stimulation 
of lipolysis with glucose. Acute stimulation with glucose caused a three-fold increase in 
release of glycerol from INS-1 cells during a 2 hour incubation period (Fig. 4.3A). 
Inhibition of MGL with JZL184 reduced glycerol release by 20% at both basal and 
stimulatory glucose. A 24-hour exposure resulted in a more potent inhibition of 
approximately 50%.   
To further support this concept, we used thin layer chromatography to determine 
the affect of JZL184 on lipid species at both basal and stimulatory glucose. [1-14C]-
Glucose was incubated with INS-1 cells overnight to label the lipid pool. Stimulation 
with 8 mM glucose for 30 min resulted in a 50% increase in total MAGs (Fig. 4.3B,C), 
consistent with a previous report (Prentki et al., 2013). At basal glucose, JZL184 nearly 
doubled total MAG species. At stimulatory glucose, JZL184 induced a greater increase 
than that seen with glucose alone. DAG species also appeared to increase when cells 
were exposed to JZL184, regardless of the glucose concentration, suggesting a block in 
GL/FFA cycling. Additionally, a dose-response of MJN110 revealed that significantly 
more MAGs were present at 10 µM compared to 1 µM in INS-1 cells, which corresponds 
to the dose-response for GSIS in which 1 µM was not very effective (Fig. S1.3). This is 
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important because the reported IC50 of MJN110 is ~10 nM, 100 times lower than 1 µM. It 
is possible that transport of MJN110 into the cell is low, which would explain this 
discrepancy.    
Alterations in [Ca2+]i with JZL184 in response to glucose and KCl/DZ 
The final common step in the triggering pathway of GSIS and depolarization is a 
rise in cytosolic [Ca2+]i, which directly promotes the fusion of insulin granules with the 
plasma membrane (De Marchi et al., 2014; Gauthier and Wollheim, 2008). The ability of 
JZL184 to inhibit both GSIS and KCl/DZ induced insulin secretion implied a strong 
likelihood that [Ca2+]i was reduced in response to these stimuli. We tested this concept 
using the cytosolic [Ca2+]i indicator fura-2. Rat islets were perifused with basal glucose 
followed by an increase to 15 mM with and without JZL184, similar to what was done in 
the insulin secretion perifusions. A clear sustained rise in cytosolic [Ca2+]i was observed 
in response to 15 mM glucose (Fig. 5.3A). However, exposure of the islets to glucose 
plus JZL184 significantly inhibited this increase over the time course observed. 
Similarly, the peak increase in intracellular [Ca2+]i induced by KCl/DZ was slightly 
inhibited by JZL184 and the sustained phase was decreased by more than half in INS-1 
cells (Fig. 5.3B).  
Decreased LC-CoA in cells with reduced MGL activity 
We have previously documented a key role of LC-CoA as a metabolic coupling 
factor in GSIS (Corkey et al., 2000; Deeney et al., 2000). An increase in glucose flux in 
the β-cell stimulates an elevation of TCA cycle intermediates and the conversion of 
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citrate to malonyl-CoA in the cytosol (Corkey et al., 1989). The inhibition of CPT-1 by 
malonyl-CoA results in an increase in cytosolic LC-CoA, which may be rapidly 
converted to other downstream FA signaling molecules including phosphatidic acid, 
DAG and triglycerides. Increased glucose flux also stimulates lipolysis and GL/FFA 
cycling, which both produces and consumes LC-CoA (Winzell et al., 2006). The net 
result is a marked reduction of the major mitochondrial pool of LC-CoA due to malonyl-
CoA inhibition of LC-CoA entry, and a transient rise in cytosolic levels. Acute 
stimulation of INS-1 cells with 8 mM glucose caused a 25% reduction in total LC-CoA 
levels, likely a result of a reduction in the mitochondrial pool (Fig. 6.3). Incubation with 
JZL184 for 30 minutes caused a further reduction of LC-CoA at both basal and 
stimulatory glucose of approximately 40% and 25% respective to their own controls. A 
60-minute incubation in JZL184 induced no further reduction compared to 30 minutes.   
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DISCUSSION 
Herein we have demonstrated a role for MGL activity in GSIS. Inhibition of MGL 
resulted in a pronounced defect in the sustained phase of GSIS. Importantly, we were 
able to demonstrate that this effect was partially a result of reduced [Ca2+]i in response to 
glucose. Consistent with this, depolarization of the plasma membrane with KCl/DZ 
resulted in a similar but slightly smaller peak rise in [Ca2+]i with concurrent JZL184 
incubation and decreased the sustained phase [Ca2+]i rise. Inhibition of MGL also caused 
a reduction in LC-CoA, an important coupling factor derived endogenously from lipid 
stores during lipolysis.  
The role of LC-CoA in GSIS has been debated in the literature (Corkey et al., 
2000). The well documented increase in malonyl-CoA competitively inhibits CPT-1, 
effectively blocking the transfer of LC FAs into the mitochondria for β-oxidation 
(McGarry and Foster, 1980). The resulting increase in cytosolic LC-CoA is then directed 
into complex lipid signaling molecules such as DAG and phosphatidic acid and also 
consistent with increased triglyceride stores for which LC-CoA is a precursor. In 
addition, LC-CoA itself can directly induce exocytosis and serves as a substrate for the 
acylation of proteins (Deeney et al., 2000). The reduction of LC-CoA we observed with 
glucose is consistent with the fact that the CoA pool is largest in the mitochondria, thus 
inhibition of CPT-1 causes a significant reduction in total LC-CoA even though cytosolic 
LC-CoA is likely elevated, at least transiently. The reduction in LC-CoA caused by 
inhibition of MGL likely plays a significant role in the documented reduction in insulin 
secretion due to a late direct or acylation effect on exocytosis. Interestingly, inhibition of 
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MGL potently reduced the second phase of GSIS, which may be dependent on granule 
movement to the plasma membrane, whereas the initial phase of secretion that was less 
affected reflects largely already docked granules (Wang and Thurmond, 2009).   
The components that are responsible for sustained secretion are not entirely clear, 
although complex lipid signaling species play an important role. On the other hand the 
triggering pathway, which is primarily thought to be responsible for the first phase of 
secretion, is mainly driven by [Ca2+]i influx. Our data suggest that the triggering of 
insulin secretion requires signals in addition to [Ca2+]i, which we have previously 
suggested (Erion et al., 2015). It is unclear from our data whether the effect of MGL 
inhibitors was due to a missing lipid signal or because of the buildup of an inhibitory 
signaling molecule. The most likely candidate for signal buildup is one or several MAG 
species, though we cannot rule out the possibility that a DAG species, which are also 
elevated as a result of the MGL inhibitor, may also play a role. It should be noted that 
McGarry demonstrated that there was no GSIS in fasted perfused pancreas without 
addition of FFA (Stein et al., 1996). 
Three different MGL inhibitors significantly decreased both GSIS and 
depolarization-induced secretion. Detailed studies of one inhibitor, JZL184 indicated that 
it impacted signaling at both LC-CoA and cytosolic Ca2+. There is a potential relationship 
between these two entities as LC-CoA has been shown to affect KATP channels and L-
type Ca2+ channels. Multiple groups have demonstrated that LC-CoA activates KATP 
channel and blunts Ca2+ entry (Branstrom et al., 1998; Gribble et al., 1998). However, our 
data documents a decrease in LC-CoA and a decrease in [Ca2+]i, which goes in the 
 	88	
opposite direction and suggests that the MGL inhibitors are not affecting KATP channels. 
Additionally, because an affect is still observed with KCl and DZ, which takes offline the 
KATP channel, an affect on the KATP channel is unlikely. A role for LC-CoA in mediating 
Ca2+ influx through L-type Ca2+ channels has been documented (Tian et al., 2008). 
However, we cannot rule out the possibility that MGL inhibitors affect [Ca2+]i via an 
affect on Ca2+ stores. These data differed from other published studies showing that 
ABHD6 is the primary monoglyceride lipase in β-cells and is essential for GSIS (Zhao et 
al., 2014).   
Recent publications by the Prentki group may clarify these apparent 
discrepancies. They observed differences in cellular distribution and in particular that 
ABHD6 is localized to the plasma membrane whereas MGL is not. Most importantly, 
they recently documented major non-specificity of different lipase inhibitors (Iglesias et 
al., 2016). First, JZL184 was found to inhibit not only MGL, but also two other MG 
lipases, FAAH and carboxyesterase-1 and to a lesser extent ABHD6. Thus our data do 
not identify a single target for inhibitor activity, although it is clear from the increase in 
MAGs following treatment that lipase activity was effectively inhibited. Secondly, the 
Prentki group compared enzymes and inhibitors in mouse and human cells. Many 
differences in inhibitor effectiveness were observed between species. Since we used rat, 
the possibility of additional differences must be considered. Finally, our previous studies 
with exogenously added mono-oleoyl-glycerol showed an increase in basal secretion that 
we did not find in response to intracellular accumulation of MAGs suggesting either an 
effect of the specific species or specific localization of the internally generated MAGs 
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(Saadeh et al., 2012). It is interesting to note that exogenous addition of mono-oleoyl-
glycerol increased LC-CoA, whereas inhibition of MGL decreased LC-CoA and did not 
affect basal secretion. This strongly implicates LC-CoA as an important regulator of 
basal insulin secretion and builds upon numerous studies showing that chronic incubation 
of β-cells with exogenous lipid increases basal insulin secretion (Bollheimer et al., 1998). 
Several previous papers have characterized the role of MAGs and MGL in the 
regulation of GSIS. Li et al. used the MGL inhibitor URB602 and observed an 
enhancement of insulin secretion at both basal and stimulatory glucose concentrations in 
MIN6 cells and human islets (Li et al., 2012). This increase in insulin secretion coincided 
with a rapid increase in [Ca2+]i influx, which is not sustained. In contrast, we observed a 
marked inhibition of both glucose and KCl-induced insulin secretion using the same 
inhibitor, URB602. Several factors may explain the apparent discrepancy between this 
result and our own data. Our experiments were conducted over a longer time frame and 
therefore a transient increase in insulin secretion may have been masked by a later 
prolonged decrease, which Li et al. also observed. While we cannot conclude that the 
pharmacological inhibitors used in our study were specific, we were able to measure both 
a reduction in glycerol secretion and a definitive increase in total MAG accumulation 
using thin layer chromatography, thereby demonstrating that indeed the drugs used did 
inhibit MAG hydrolysis, as expected.  
A recent report by Zhao et al. clearly demonstrates that pharmacological or 
genetic inhibition of the plasma membrane hydrolase, ABHD6, stimulates GSIS possibly 
by action of increased MAGs binding to the exocytotic protein Munc13-1 (Zhao et al., 
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2014). While it was argued that ABHD6 is the predominant lipase that breaks down 
MAG in β-cells and that MGL is expressed at low levels, others have demonstrated that 
MGL is expressed in both human and rodent β-cells (Li et al., 2012). These authors also 
demonstrate that in INS-1 cells, 1 µM JZL184 increases MAG species, but has no effect 
on insulin secretion, similar to what we have shown (Fig. 1.3A). Thus INS-1 cells require 
a higher concentration than islets, possibly due to their large intracellular lipid stores 
when cultured at high glucose (Erion et al., 2015).   
In summary, we have demonstrated that pharmacological inhibition of MGL 
reduces both KCl and glucose induced insulin secretion. This reduction is the result of 
processes that may partially involve the classical Ca2+-dependent pathway via which 
glucose and KCl induce insulin secretion as well as a failure to increase cytosolic LC-
CoA. We cannot rule out the possibility that the build-up of specific MAG species in a 
specific location may be responsible for the observed inhibition of GSIS. Alternatively, 
lack of specificity of the lipase inhibitors may alter other lipid species not measured. 
Further research will be needed to determine the role of specific MAG species on GSIS.  
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Figure 1.3.  Inhibition of MGL reduced GSIS in INS-1 cells and isolated rat islets.  
(A) JZL184 dose-dependently reduced GSIS during static incubations in INS-1 cells 
(n=3).  (B) JZL184 (10 µM) reduced GSIS in INS-1 cells regardless of the temporal 
exposure (n=3).  (C) INS-1 cells demonstrated a partial recovery of GSIS following the 
removal of JZL184 (10 µM) for 2 hours (n=3).  (D) MJN110 dose-dependently reduced 
GSIS during static incubations in INS-1 cells (n=4).  (E) URB602 (50 µM) inhibited 
GSIS during static incubation in INS-1 cells (n=3).  (F) JZL184 dose-dependently 
reduced GSIS in isolated whole rat islets during a static incubation (n=3).  Error bars 
represent S.E. from independent experiments (*, p<0.05). 
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Figure 2.3.  JZL184 reduced sustained insulin secretion during glucose stimulation 
in whole isolated rat islets.  
Islets were perifused with basal glucose (3 mM) KREBS for approximately 10 minutes 
followed by a 30-minute perifusion with 15 mM glucose with or without 10 µM JZL184.  
At 40 minutes the islets were perifused with 15 mM glucose KREBS with 0.4 mM DZ 
and 30 mM KCl with or without 10 µM JZL184. n = 3 independent experiments from 
different islet isolations.  Error bars represent S.E. and are displayed every 4th data point 
for clarity.  All points after 23.1 minutes were significantly different (p<0.05). 
 
 
 
 
 
 
 
 	93	
 
Figure 3.3.  JZL184 inhibited KCl-induced insulin secretion.  
Insulin secretion from batch incubations of (A) INS-1 cells and (B) dissociated rat islets 
(n=3 independent experiments for both A and B).  Error bars represent S.E. (*, p<0.05). 
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Figure 4.3. Exposure to JZL184 reduced glycerol release and increased MAG 
species in INS-1 cells.   
(A) Incubation with 10 µM JZL184 time-dependently reduced glycerol release at both 
basal and stimulatory glucose (n=6).  (B) Acute exposure to JZL184 for 30 minutes 
increased total MAG species at both basal and stimulatory glucose.  (C) Quantitation of 
total MAGs from 4 experiments.  Error bars represent S.E. from independent experiments 
(*, p<0.05). 
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Figure 5.3.  Small decreases in Ca2+ influx following exposure to JZL184 in isolated 
rat islets and INS-1 cells.   
(A) Islets were brought from 3 mM glucose to 15 mM glucose with or without 10 µM 
JZL184 and cytosolic Ca2+ was documented using the probe fura-2 (n=4).  (B) INS-1 
cells were brought from 2 mM glucose plus 0.25 mM DZ to 8 mM glucose with 0.25 mM 
DZ and 30 mM KCl with or without 10 µM JZL184 (n=3).  Ca2+ levels are expressed as 
the fura-2 ratio at 340/380 nm. 
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Figure 6.3. Significant reduction in total LC-CoA following acute treatment of INS-
1 cells with JZL184.  
 Cells were exposed to JZL184 at both basal and stimulatory glucose and LC-CoA was 
measured as described in the methods (n=3). Error bars represent S.E. from independent 
experiments (*, p<0.05). 
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Figure S1.3. MJN110 dose-dependently increases MAG species.   
Lane 1: Monooleoylglycerol standard. Lane 2: Monooleoylglycerol standard + 
diacyglycerol standard from pig liver. Lane 3: INS-1 (cultured in 11 mM glucose) cells 
exposed to 8 mM glucose for 30 minutes. Lane 4: Cells exposed to 8 mM glucose + 1 µM 
MJN110. Lane 5: Cells exposed to 8 mM glucose + 10 µM MJN110. Lane 6: 
Dioleoylglycerol standard (*note: TLC done on same plate but spliced together to remove 
irrelevant lane.) Experiment was performed one time. 
 
 
Figure 8 
 
 
Part 3 
Additionally, I have worked with a graduate student in Dr. Paul Pilch’s laboratory attempting to decipher the 
role of Adiporedoxin (ADRX) in beta-cell function. ADRX is a protein discovered by the Pilch lab and believed 
to be an ER resident protein critical in the proper folding of disulfide bonds, and is expressed highly in 
adipocytes. We have shown that the protein is also expressed in islets and influences insulin secretion 
depending on it’s level of expr ssi n. Figure 9 demonstrates that isets from ADRX KO mice have increased 
insulin content (Figure 9) and normal insulin secretion based on an absolute amount, but reduced insulin 
secretion when normalized to insulin content (Figure 10). This data fits with results obtained from the Pilch lab 
where they demonstrated that knockout of ADRX in adipocytes reduces secretion of adipokines (including 
adiponectin) and overexpression of ADRX enhances secretion of these same adipokines.  
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ABSTRACT 
Iron stores have a strong positive correlation with the development of T2D, however, 
little is known about its direct affect on β-cell function. Previous work in our laboratory 
and others has demonstrated that ROS play an important role in regulating insulin 
secretion. We tested the hypothesis that iron, which is known to increase cellular ROS, 
also stimulates insulin secretion. We found that holotransferrin (HT), iron citrate and iron 
ascorbate enhanced insulin secretion at both basal and stimulatory glucose in INS-1 
(832/13) cells. The increased insulin secretion was associated with a concomitant 
increase in lipid peroxidation and was reversed by the antioxidant N-acetylcysteine 
(NAC). The increased secretion was not associated with any changes in [Ca2+]i and was 
not affected by the KATP channel agonist DZ. Our results suggest that iron can trigger 
insulin secretion independent of Ca2+ and may be partially responsible for the 
hypersecretion of insulin observed in obesity and in patients with iron overload.
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INTRODUCTION 
 Iron is a critical metal that must be incorporated into the diet, as iron deficiency 
results in anemia. Iron plays an important role in a variety of cellular processes including 
oxidative metabolism and DNA synthesis, among others (Zhang, 2014). This metal can 
be found in both the ferric (Fe3+) and ferrous (Fe2+) states. The ability to undergo multiple 
states of oxidation underlies the capacity of iron to participate in redox cycling, the 
process by which iron transitions between these two states. In doing so, iron is able to 
catalyze electron transfer. While this property is vital to life, it also leads to the 
generation of ROS, which can be toxic to cells if not adequately neutralized. Normally 
iron is stored in an inert state bound to ferritin within the cell (Wang and Pantopoulos, 
2011). This is important as iron can readily undergo the Fenton reaction in which 
hydroxyl radicals, a particularly damaging species of ROS, are produced (Winterbourn, 
1995).  
 The concept that ROS may serve as an important signaling molecule has only 
recently garnered interest (Thannickal and Fanburg, 2000). ROS within the cell are 
generated from two primary sources; mitochondria via oxidative metabolism and the 
plasma membrane enzyme NADPH oxidase. ROS from mitochondria are generated 
primarily by NADH dehydrogenase at Complex I and at Complex III in the form of 
superoxide (O2-) (Maechler et al., 2010). The enzyme superoxide dismutase then 
scavenges this to yield hydrogen peroxide (H2O2). Two enzymes, catalase and 
glutathione peroxidase, neutralize the hydrogen peroxide to water. Iron can also react 
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with hydrogen peroxide to generate hydoroxyl radicals (OH), a particularly potent 
species of ROS.   
 β-cells have low antioxidant capacity compared to almost all other cell types 
(Lenzen et al., 1996). In particular, the enzymes catalase and glutathione peroxidase are 
expressed at very low levels (Tiedge et al., 1997). This has lead many to the conclusion 
that β-cells may be particularly susceptible to apoptosis under conditions of ‘oxidative 
stress’. While this may be accurate, ROS may also serve as an important secondary 
messenger in the coupling of nutrient influx to insulin secretion. This particularly makes 
sense, as hydrogen peroxide is stable compared to superoxide, thus making it a suitable 
secondary messenger candidate. It is well known that increased glucose oxidation, as 
occurs during GSIS, increases ROS levels. Our group and others have shown increasing 
cellular ROS levels either directly or indirectly increases insulin secretion, particularly at 
basal glucose (Leloup et al., 2009; Pi et al., 2007; Saadeh et al., 2012). While the 
mechanism underlying this phenomenon has not been completely elucidated, it may 
involve modification of thiols within exocytotic proteins or inhibition of phosphatases. 
 Herein, we show that multiple forms of iron stimulate both basal and GSIS in a 
ROS-dependent manner. This effect was not due to a rise in cytosolic Ca2+ as the effect 
persisted even when Ca2+ influx was inhibited.  
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MATERIALS AND METHODS   
Ethics Statement − This study was carried out in strict accordance with the 
recommendations in the guide for the care and use of Laboratory Animals and the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee at Boston University Medical Center (Boston University Medical 
Center Animal Welfare Assurance: A-3316-01).  
Islets − Islets were isolated from male Sprague-Dawley rats (150-250 g) as previously 
described (Erion et al., 2015). Briefly, the rat pancreas was excised and minced in 0.5 mL 
of HBSS containing 10 mM HEPES and adjusted to pH 7.4. The minced pancreas was 
then shaken in 5.5 mL HBSS with 3.3 mg collagenase P (1.7 units/mg) (Roche, 
Indianapolis, IN) in HBSS for 3 minutes at 37oC. The digested pancreas was then washed 
with HBSS supplemented with 0.1% defatted BSA (EMD Millipore, Billerica, MA) and 
further isolated by centrifugation through a Histopaque gradient (Sigma, St. Louis, MO).  
Isolated islets were cultured overnight in RPMI 1640 (11 mM glucose) without phenol 
red containing 10% FBS, 5 mM glutamine, 50 IU/mL penicillin, 50 µg/mL streptomycin.  
Islets were dissociated using accutase (Sigma, St. Louis, MO). Briefly, approximately 
100 islets were incubated with 1 mL accutase at 37oC for 10 min and plated at a density 
of 2000-4000 cells/well in multiwell culture plates using matrigel (BD Biosciences, 
Billerica, MA). 
INS-1 (832/13) Cells − INS-1 (832/13) cells were cultured in RPMI (11 mM glucose) 
with phenol red as above with the addition of 1 mM sodium pyruvate, 10 mM HEPES 
and 50 µM β-mercaptoethanol as previously described (Erion et al., 2015). 
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Insulin Secretion − Insulin secretion was measured from INS-1 cells grown for at least 3 
days to approximately 85% confluence in 48- and 96-well plates as we have described in 
previous work (Saadeh et al., 2012). Briefly, INS-1 cells were preincubated with RPMI 
containing 2 mM glucose without FBS for 2 hours prior to a 30-minute preincubation 
with 2 mM glucose in KREBS at 37oC. The KREBS contained 119 mM NaCl, 4.6 mM 
KCl, 5 mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 
20 mM HEPES, 0.05% BSA, pH 7.4. Dissociated islets and whole rat islets (6 islets/tube) 
were preincubated in 3 mM glucose in KREBS at 37oC for 30 minutes prior to measuring 
secretion. Following preincubations, INS-1 cells and islets were cooled on ice before 
experimental solutions were added. Cells were incubated for 60-120 min at 37oC, cooled, 
and sampled for insulin secretion. Insulin was measured by HTRF insulin assay (CisBio, 
Bedford, MA).   
Oxygen Consumption − O2 consumption was assessed in INS-1 cells using the Seahorse 
Extracellular Flux Analyzer XF24 machine (Seahorse Bioscience, Billerica, MA) as 
described previously (Saadeh et al., 2012). Briefly, cells were grown in Seahorse V.7 24-
well culture plates to a density of approximately 120,000 cells per well using culture 
conditions described above. Cells were incubated prior to the experiment in the same 
manner as insulin secretion experiments and measurements were performed in KREBS. 
Cells were placed in 2 or 8 mM glucose and test compounds were injected while 
maintaining the glucose concentration and respiration was monitored. Oligomycin (5 
µM), FCCP (2.5 µM) and antimycin (10 µM) were injected while maintaining the glucose 
concentration to calibrate. 
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Ca2+ Determination – [Ca2+]i was measured using fura-2 AM (Invitrogen, Carlsbad, CA) 
as previously described (Saadeh et al., 2012). Briefly, INS-1 cells were loaded with fura-
2 (2 µM) for 30 minutes in 2 mM glucose RPMI with 0.1% pluronic acid (Thermo Fisher 
Scientific, Waltham, MA) on 35 mm 4-quadrant glass bottom dishes (MatTek, Ashland, 
MA). A 30-minute cleavage period in 2 mM glucose KREBS buffer was then initiated 
following removal of the fura-2. Imaging was performed on an Olympus DSU spinning 
disk confocal microscope at 20X magnification and 37°C. Fluorescent images were 
captured every 10 seconds with wavelengths of 340 nm/380 nm dual excitation and 510 
nm emission. Data were analyzed using NisElements software.  
Lipid peroxidation – INS-1 cells were treated as for insulin secretion. Lipid peroxidation 
was subsequently assessed using a modified thiobarbituric acid assay as described by our 
laboratory previously (Nocito et al., 2015). Briefly, cells were exposed to experimental 
compounds in KREBS buffer, followed by incubation in a 0.4% 2-thiobarbituric 
acid/10% acetic acid/0.0625 N NaOH solution at 90°C for 60 minutes. Cells were then 
scraped and spun at 15,000 g for 5 minutes in 1.5 mL eppendorf tubes. The supernatant 
was then collected and measured on a TECAN M1000 plate reader with an 
excitation/emission wavelength of 515/553 nm. 
Statistics − The data are presented as the mean of independent experiments ± S.E.M. 
Statistical significance was determined by two-tailed Student’s t test or by a one-way 
analysis of variance (ANOVA) followed by Bonferroni’s post hoc test where indicated. A 
p-value of <0.05 (*) was considered significant. 
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RESULTS 
Iron increased basal and GSIS 
We first determined the effect of multiple forms of iron on basal (2 mM glucose) 
and GSIS (8 mM glucose) in INS-1 cells. Iron is transported in the blood by transferrin, 
which undergoes receptor-mediated endocytosis to enter the cell. Acidification of the 
endosome releases iron into the cell. Figure 1.4A demonstrates that HT (transferrin bound 
to one Fe3+ molecule) dose-dependently stimulated insulin secretion at basal and high 
glucose. The half-maximal concentration (EC50) of HT was approximately 18 µM for 
basal insulin secretion and 10 µM for GSIS. Iron ascorbate also increased insulin 
secretion (Fig 1.4B). At basal glucose, 5 µM iron ascorbate effectively doubled the 
amount of insulin secreted and higher concentrations did not increase this effect. A 
similar result was observed at stimulatory glucose, although higher concentrations than 5 
µM did further increase insulin secretion (Fig 1.4B). Additionally, 10 µM iron citrate 
caused a 65 and 45% increase in insulin secretion at basal and stimulatory glucose, 
respectively (Fig 1.4C).   
 NAC is a precursor to the endogenous antioxidant glutathione and also has 
intrinsic antioxidant capacity (Aruoma et al., 1989). Previous studies in β-cells have 
demonstrated that administration of antioxidants inhibits GSIS in vitro (Pi et al., 2007). 
We titrated concentrations of NAC and found that concentrations greater than 1 mM 
acutely inhibited GSIS in INS-1 cells (data not shown). We found that 0.75 mM NAC 
was able to inhibit the increase in insulin secretion observed with 25 µM HT without 
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significantly affecting insulin secretion in control cells (Fig 1.4D). These data imply that 
iron is likely stimulating insulin secretion in a ROS-dependent manner. 
Iron increased lipid peroxidation in INS-1 cells 
To determine if iron was induced ROS production as suspected, we measured the 
amount of lipid peroxidation in cells following exposure to iron. Lipid peroxidation was 
approximately twice as high following a 30-minute exposure to iron (Fig 2.4). This was 
completely blocked if the iron chelator deferoxamine was added concurrently. 
HT increased oxygen consumption at basal glucose 
In order to determine what role the classical pathway for insulin secretion played 
in the iron affect, we measured oxygen consumption in response to relevant 
concentrations of HT. Respiration was dose-dependently increased at both basal glucose 
concentrations in response to HT (Fig 3.4). Although the effect of HT to stimulate 
respiration was clear, at 25 µM HT, only a 10% increase was observed. On the other 
hand, stimulation with 8 mM glucose caused an approximately doubling of respiration 
(data not shown). Thus, the effect of iron to stimulate respiration was modest and 
insignificant.  
Iron does not increase Ca2+ influx 
We next tested whether Ca2+ played a role in the iron affect on insulin secretion. 
Using the Ca2+ sensor fura-2, we monitored changes in [Ca2+]i in response to iron at 2 
mM glucose (Fig 4.4A). As expected, glucose stimulated a rise in average [Ca2+]i,. There 
was no evidence of any change in Ca2+ dynamics in response to 10 µM iron citrate. There 
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was a trend for 25 µM HT to cause a rise in average cytosolic Ca2+, though the results did 
not reach significance. To confirm that Ca2+ was not the main mechanism underlying the 
effect of iron on insulin secretion, we tested whether DZ, a KATP channel agonist that 
inhibits extracellular Ca2+ influx, could inhibit iron-induced insulin secretion. At basal 
glucose, DZ did not inhibit the ability of iron citrate to enhance insulin secretion (Fig 
4.4B). At stimulatory glucose, DZ inhibited insulin secretion to the same level as at basal 
glucose, likely indicating the activation of a constitutive pathway not dependent on a rise 
in cytosolic Ca2+.    
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DISCUSSION 
 Herein we demonstrated that exogenous iron stimulates insulin secretion in a 
ROS-dependent manner. Unlike previous publications in which increased cellular ROS 
generated by direct addition or by other agents was shown to stimulate only basal insulin 
secretion, we found that iron increased both basal and GSIS. We have shown that, in 
INS-1 cells, the effect of iron on insulin secretion is not due to any alteration in Ca2+ 
dynamics, but rather to activation of a constitutive pathway of insulin secretion.   
There is very limited research for the role of iron in β-cell function and T2D. 
Leptin deficient (ob/ob) mice, which are hypephagic and obese, demonstrate normalized 
glucose tolerance, reduced HI and improved β-cell function when iron is restricted via 
diet or chelation (Cooksey et al., 2010). Another study using Otsuka Long-Evans 
Takushima fatty rats showed that reduction of body iron stores increased insulin 
secretion, possibly by inhibiting apoptosis of β-cells (Minamiyama et al., 2010). Mice 
with a global knockout of the cellular iron transporter DMT1 have impaired GSIS from 
isolated islets (Hansen et al., 2012). Taken together, there is clearly a role for iron in β-
cell function; however, determination of the optimal range for β-cell function is 
necessary.        
To the best of our knowledge, this is the first report demonstrating an acute ability 
of iron to stimulate insulin secretion. Because Ca2+ influx in response to iron was not 
increased and DZ was unable to inhibit the increased secretion, a pathway other than the 
classical secretion pathway is likely to be the cause. It is likely that iron bound to 
transferrin increased respiration due to the fact that transferrin internalization into the cell 
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and subsequent processing is energy intensive (Pantopoulos et al., 2012). While ROS has 
been shown to be imperative for GSIS, the precise target has not been elucidated. We 
showed increased lipid peroxidation with iron, though a study published that multiple 
peroxidized lipid species inhibit GSIS from isolated rat islets (Miwa et al., 2000). Thus, it 
is likely that the increased peroxidized lipid observed with iron incubation is simply a 
result of increased ROS production, and is not the effector signal that enhanced insulin 
secretion.  Other possible targets include protein phosphorylation. ROS is known to 
inhibit phosphatase activity, which leads to increased global protein phosphorylation 
(Wright et al., 2009).     
While others have shown that reduction of endogenous ROS via antioxidant 
administration inhibits GSIS, this is the first example of stimulation of GSIS via an 
increase in ROS (Leloup et al., 2009). It is possible that iron produces unique species of 
ROS via Fenton chemistry that are not associated with normal GSIS. It has been 
proposed that hydrogen peroxide is the effector ROS species because of the low 
expression of hydrogen peroxide scavenging enzymes in β-cells. Thus, little research has 
been done exploring the role of other species of ROS. It is interesting that the antioxidant 
NAC was able to reverse the effect of iron on insulin secretion. NAC is both an 
antioxidant and a precursor to glutathione synthesis, though the latter is thought to 
account for the majority of its antioxidant capacity (Gibson et al., 2009). Glutathione 
serves to reduce endogenous scavenging enzymes, including glutathione peroxidase. The 
fact that these enzymes are lowly expressed in β-cells requires speculation as to how 
NAC is truly affecting insulin secretion. NAC has weak antioxidant capacity against 
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hydroxyl radicals, a byproduct of Fenton chemistry, (Samuni et al., 2013). Additionally, 
glutathione has antioxidant capacity independent of its ability to reduce glutathione 
peroxidase and other antioxidant enzymes (Rushworth and Megson, 2014). 
The classical model of GSIS stipulates that a rise in [Ca2+]i ‘triggers’ insulin 
secretion and other signals ‘amplify’ the insulin secretion caused by the calcium rise. 
This model is supported by the fact that many secretagougues only cause stimulation at 
high glucose. Examples include acute addition of FAs and GLP-1 (which increases 
cAMP). Recently, it was shown that through a cocktail of stimuli, insulin secretion can be 
‘triggered’ without a rise in [Ca2+]i (Komatsu et al., 2002; Takei et al., 2013). However, 
these studies also require an increase in nutrient levels. Our study documents the ability 
of ROS to trigger insulin secretion without a rise in nutrients or [Ca2+]i. This indicates 
that ROS likely acts directly on the exocytotic machinery to enhance insulin secretion. It 
is interesting to speculate that other chronic conditions which stimulate insulin secretion 
at basal glucose, namely chronic exposure to high lipid conditions, may involve increased 
ROS production.       
The association of iron stores with development of T2D and data presented in this 
paper fit with our model that HI may be a primary cause in the progression to T2D 
(Corkey, 2012a). Thus, excess iron, either from the diet or genetic abnormalities, may 
stimulate insulin secretion inappropriately and cause metabolic dysfunction. Namely, 
high insulin levels can cause IR and promotes weight gain, both prominent features of 
T2D (Shanik et al., 2008). Long-term exposure β-cells to excess iron has the potential to 
cause apoptosis and β-cell failure, which distinguishes those individuals that develop 
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T2D from those that maintain normoglycemia (Halban et al., 2014). In support of this, 
patients with iron overload from HH had significantly increased insulin secretion when 
glucose tolerance was normal but reduced insulin secretion when glucose tolerance was 
abnormal (McClain et al., 2006).   
In summary, we have demonstrated that multiple forms of iron stimulate insulin 
secretion at both basal and stimulatory glucose in a ROS-dependent manner. This 
stimulation occurred independently of a rise in cytosolic Ca2+ and was not inhibited by 
KATP-channel agonists. Further research will need to be done to identify the specific 
targets of iron-induced insulin secretion and to establish the optimal iron range in humans 
for metabolic health. 
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Figure 1.4. Iron stimulated insulin secretion at basal and high glucose in INS-1 cells.  
Iron in the form of (A) HT and (B) iron ascorbate dose-dependently increased basal and 
GSIS. (C) Iron citrate increased basal and GSIS. (D) The antioxidant NAC normalized 
the increased basal and GSIS caused by 25 µM HT. N = 4, 2, 6 and 4 independent 
experiments with 3-4 replicates per condition per experiment. Error bars represent S.E. 
from independent experiments (*, p<0.05). 
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Figure 2.4. Iron increased peroxidized lipid that was reversed via chelation with 
deferoxamine.  
30-minute exposure of INS-1 cells to 10 µM iron citrate increased lipid peroxidation. 
When added concurrently, the iron chelating agent DFO inhibited this effect. N = 3 
independent experiments with 3 replicates per condition. Error bars represent S.E. from 
independent experiments (*, p<0.05). 
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Figure 3.4. Significantly increased respiration in INS-1 cells in response to HT at 
basal glucose.  
Iron or buffer was injected at 39 minutes and the response was plotted as a percent 
increase above the final baseline time point. At 74 minutes, 5 µM oligomycin was added. 
At 88 minutes, 2.5 µM FCCP was injected. At 96 minutes, 10 µM antimycin A was 
injected. N = 2 independent experiments with 4 replicates per condition. Error bars 
represent S.E. from independent experiments (*, p<0.05). No significant differences were 
detected for 25 µM HT versus control.  	
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Figure 4.4. Small increase in [Ca2+]i in response to HT but not iron citrate at basal 
glucose.  
(A) The ratiometric dye fura-2 was used to measure [Ca2+]i in response to multiple forms 
of iron in INS-1 cells. After establishment of a stable baseline, buffer was added as an 
addition control at 5 minutes (blue). The response to high glucose (red), 25 µM HT 
(green), and 10 µM iron citrate were monitored after their addition at 5 minutes. (B) 
Quantification of the change in average fura-2 ratio from 0-5 minutes to 10-30 minutes in 
data derived from (A). (C) 10 µM iron citrate increased insulin secretion even with 
concomitant exposure to DZ. N = 3 and 4 independent experiments for (A, B, C)). Data 
points reflect the mean and error bars represent ± S.E.. All points in the response to high 
glucose were significant after 9.6 minutes for (A). Insulin secretion at 2 mM glucose was 
significantly higher (p < 0.05) with 10 µM iron citrate both in the absence and presence 
of 0.4 mM DZ. Insulin secretion at 8 mM glucose with 10 µM iron citrate and 0.4 mM 
DZ was also significantly elevated relative to insulin secretion at 2 mM glucose in control 
cells.
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CHAPTER FIVE: General Discussion 
 T2D is a complex disease that involves many organ systems. However, genome 
wide association studies have revealed that the majority of genes related to development 
of T2D are linked to the pancreatic β-cell, emphasizing the importance of β-cell 
dysfunction (Florez, 2008). The accepted model for the progression of T2D stipulates that 
IR leads to β-cell compensation followed by a progressive decline until β-cell failure. 
However, current therapeutic options that enhance insulin sensitivity or increase insulin 
secretion cannot reverse the disease, and have a variety of undesirable side effects. Only 
recently has it become apparent that reversal of the disease is indeed possible through 
bariatric surgery or prolonged fasting. Both of these situations rapidly normalize HI, 
restore insulin secretion in response to glucose and improve glucose tolerance within a 
matter of days to weeks (Lim et al., 2011; Reed et al., 2011). This occurs prior to any 
substantial change in IR. Understanding both what causes HI and β-cell dysfunction at a 
cellular level may help to develop novel therapeutics to not only better treat but also 
potentially reverse T2D. In the prior three chapters of this thesis I describe two 
mechanisms for how HI may occur and two mechanisms for how β-cell failure may 
develop. I show that hypersecretion of insulin can be caused by both a left-shift in GSIS 
(Chapter 2) and by iron (Chapter 4). I also demonstrate that β-cell failure can occur 
following degranulation of the β-cells via chronic culture in high lipid/glucose (Chapter 
2) and by inhibiting MGL (Chapter 3).  
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A new model for the origins of HI in obesity 
In Chapter Two, I show that chronic culture of clonal β-cells and isolated islets in 
high glucose and/or high lipid increases intracellular lipid stores and left-shifts the 
concentration dependence for GSIS. This results in hypersecretion of insulin at 
submaximal glucose concentrations. Previous work by other labs has documented a 
similar phenomenon in genetically obese rats and in islets cultured in a high glucose/lipid 
environment (Liu et al., 1998; Zhou et al., 1999). They propose that higher glucose flux 
as a result of increased hexokinase expression and activity is responsible for this shift in 
the dose-response curve. Due to the very low Km of hexokinase (~100 µM), outside of the 
physiological glucose range, increased activity in the β-cell should markedly lower the 
threshold for GSIS. While our data do show that rates of basal respiration are higher in 
clonal β-cells with increased lipid, this can be mostly accounted for by a mitochondrial 
leak (Figure 8.2F). Additionally, we show no difference in either glucose phosphorylating 
capacity or glucose flux into the β-cell despite still retaining a left-shift in GSIS. In 
accordance with this, Ca2+ dynamics in response to glucose were not different in either 
left- or right-shifted β-cells. There also were no differences found in the dose-response of 
the amplification pathways stimulated by glucose. We did, however, document a change 
in the sensitivity of exocytosis to Ca2+ as a likely candidate responsible for the left-shifted 
glucose dose-response associated with high lipid stores.  
The discrepancy between these results (hexokinase vs Ca2+ sensitivity) can likely 
be explained by the dose of FA. At intermediate levels of nutrients, we found no increase 
in basal secretion, while a left-shift in GSIS was still documented. However, when we 
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applied a very high nutrient environment to either INS-1 cells (11 mM glucose, 0.15 mM 
oleate) or isolated rat islets (11 mM glucose, 0.2 mM oleate) we did note increased basal 
insulin secretion. Thus, when intracellular lipid starts to accumulate, this may initially 
result in altered Ca2+ sensitivity leading to insulin hypersecretion. As lipid accumulates to 
higher levels, this will increase expression and activity of hexokinase and increase basal 
secretion. This timeline would appear to fit with the documented progression of β-cell 
dysfunction in obesity and T2D. Obesity is associated with increased insulin secretion at 
both fasting and stimulatory glucose (Polonsky et al., 1988a). Because fasting glucose is 
not different in the majority of obese people compared to lean people, it has been stated 
that glucose cannot be responsible for the hypersecretion of insulin observed in obesity 
(Polonsky et al., 1988a). However, if in obesity there is a different sensitivity of the β-cell 
to glucose, this could very well account for the hypersecretion at both fasting and 
intermediate glucose concentrations.  
Part of the problem with testing the current model is that KATP channel agonists, 
while effective at reducing HI in obesity and T2D, also inhibit insulin secretion when it is 
needed following nutrient ingestion. While we have identified a shift in glucose 
sensitivity as an important regulator of the hypersecretion of insulin in obesity, we also 
determined that lipid is a key regulator in this shift. Therefore, we can potentially reduce 
this lipid species pharmacologically or nutritionally once identified, and inhibit HI 
without negatively influencing insulin secretion when it is appropriate. Thus, our studies 
suggest novel approaches that include lowering lipid content to prevent development of 
T2D.  
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Mechanism underlying the change in Ca2+ sensitivity 
 The classical model for GSIS states that a rise in [Ca2+]i triggers insulin secretion 
and other signals amplify secretion caused by Ca2+. Data presented in Chapter Two 
provide evidence that this may not always be the case. Cells cultured chronically in 4 mM 
glucose elicited a robust rise in [Ca2+]i in response to 4 mM glucose. However, there was 
no increase in insulin secretion above basal in response to 4 mM glucose in these cells, 
indicating that the triggering pathway was not activated. Thus two possibilities exist to 
explain this: (1) there is a signal other than Ca2+ that is required for triggering or (2) 
something within the cell modulates its sensitivity to Ca2+ and adjusts the threshold for 
triggering. We demonstrate using permeabilized cells and EGTA-buffers set to fixed Ca2+ 
concentrations that cells with high intracellular lipid stores have a left-shifted sensitivity 
of exocytosis to Ca2+. In this experiment, the buffers contain an ATP regenerating 
system, effectively taking any differences in metabolism offline. The origin of this shifted 
Ca2+ sensitivity is at this time unclear, although many plausible explanations exist both 
directly or indirectly related to lipid. While a correlation between the S0.25 for GSIS and 
TAG content is evident, it is highly improbable that TAG itself is the effector species, as 
it is thought to be an inert molecule. 
 Several studies have previously documented that pharmacological activation of 
adenylate cyclase and PKC in the presence of nutrients can trigger insulin secretion in the 
absence of Ca2+ (Komatsu et al., 2002; Komatsu et al., 1995). However, to the best of our 
knowledge, this is the first published data documenting a rise in [Ca2+]i without a 
corresponding rise in secretion. It is possible that reduced signaling through cAMP and/or 
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PKC prevents triggering in these right-shifted cells. The tight correlation between lipid 
stores and glucose sensitivity suggests that a lipid species may affect the ability of the β-
cell to trigger insulin secretion. This would align with the observation that islets from 
fasted animals do not respond acutely to glucose unless supplemented with FA (Dobbins 
et al., 1998; Stein et al., 1996). Previous work in our lab has documented the ability of 
LC-CoA to enhance insulin exocytosis at a given cytosolic Ca2+ level (Deeney et al., 
2000). Though we did not directly measure it, it is likely that LC-CoA is concomitantly 
elevated when lipid stores are larger. LC-CoA can also serve as a substrate for the 
acylation of several proteins involved in exocytosis. Two critical exocytotic proteins, 
spynaptotagmin and SNAP25 have conserved acylation sites (Veit et al., 1996). It is 
possible that these acylation sites help to anchor the proteins to membranes, which are the 
sites for vesicle fusion and exocytosis. Chapter 5 demonstrated that a reduction in LC-
CoA reduces the ability of the cell to couple Ca2+ influx to insulin secretion, although we 
did not prove that reduced LC-CoA was causative in this. 
Very little research on the sensitivity of Ca2+ to granule exocytosis has been done 
in β-cells. Much more has been done in neuronal cells, which exhibit very similar 
exocytotic machinery to the β-cell (Jacobsson and Meister, 1996). Much of this has 
focused on the putative Ca2+ sensor within the exocytotic machinery, synaptotagmin. 
Synaptotagmin is present in β-cells and has been shown to play a critical role in the 
exocytosis of insulin granules (Gauthier and Wollheim, 2008). Phosphatidyl-inositol 4,5-
Bisphosphate (PIP2) is a membrane bound lipid species that has been shown to regulate 
the sensitivity of synaptotagmin to Ca2+ in neuronal cells (Radhakrishnan et al., 2009; 
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van den Bogaart et al., 2012). Additionally, PIP2 plays a role in the remodeling of the 
actin cytoskeleton, which is a critical component of triggering and first-phase of insulin 
secretion (Yin and Janmey, 2003). Thus, a change in membrane PIP2 levels could explain 
the left-shifted dose-response curve for GSIS and sensitivity of exocytosis to Ca2+ in cells 
with elevated lipid stores. Preliminary data done in collaboration with Dr. Lucia Rameh 
indicates that right-shifted cells have a reduced amount of PIP2 as a percentage of total 
cellular phospholipid species (Figure 2.5). Cholesterol is another lipid specie that has 
been shown to play a critical role in Ca2+ mediated exocytosis. Cholesterol mediates the 
required curvature of the plasma membrane needed for exocytosis to occur (Churchward 
et al., 2005). Other lipid species including dioleoylphosphatidylethanolamine and 
dioleoylglycerol have been found to regulate the focal curvature of the plasma membrane 
and influence Ca2+-induced exocytosis (Churchward et al., 2008). 
The concept that distinct pools of exocytotic granules may have different 
sensitivities to Ca2+ has recently garnered interest (Dolensek et al., 2011). Research has 
shown that granules designated as highly Ca2+ sensitive are by and large newly 
synthesized and reside close to the plasma membrane (Pedersen and Sherman, 2009). The 
size of the highly Ca2+ sensitive pool is increased by PKA and PKC activity (Yang and 
Gillis, 2004). Thus, chronic exposure to nutrients may increase this granule pool, even if 
as a whole the number of insulin granules is decreased. This would cause a left-shift by 
lowering the threshold for triggering by Ca2+. 
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Iron and triggering 
 While it has been known for years that ROS is an important regulator of insulin 
secretion, the exact mechanism via which it does this is not known (Prentki et al., 2013). 
We show in Chapter 4 that multiple forms of iron can enhance insulin secretion at both 
basal and stimulatory glucose in a ROS-dependent manner. Interestingly, the increased 
secretion at basal glucose was not associated with any significant change in Ca2+ entry 
into the cell. Thus, iron can ‘trigger’ insulin secretion independent of a rise in [Ca2+]i. 
This is corroborated by the result that DZ does not inhibit the stimulatory effect that iron 
has on basal insulin secretion. Our data indicate that ROS may be an important regulator 
of the triggering pathway of GSIS.  
 A possible link between the hypersecretion of insulin induced by chronic culture 
in excess nutrients and by iron may be ROS. Chronic incubation in excess nutrients in the 
form of glucose and FAs is known to increase ROS production (Barlow and Affourtit, 
2013). High flux of reducing equivalents through the electron transport chain in the 
mitochondria is believed to be the primary source of this ROS. As previously outlined 
increased ROS production induces triggering of insulin granules. The specific species of 
ROS or the mechanism by which it acts on exocytosis is not clear. Iron increased lipid 
peroxidation in INS-1 cells, which is caused by hydroxyl radicals. Iron consumes 
hydrogen peroxide and generates hydroxyl radicals via the Fenton reaction. However, 
hydrogen peroxide also appears to induce triggering, though no formal Ca2+ measurement 
is found within the paper (Pi et al., 2007). Thus, there appears to be a mechanism by 
which a general increase in cellular ROS leads to triggering of insulin granules.  
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It is also possible that ROS may alter the Ca2+ sensitivity of exocytosis such that 
the triggering may occur at a lower glucose threshold. ROS is known to inhibit 
phosphatase activity, which likely leads to increased phosphorylation of sites normally 
unphosphorylated in the basal state. These sites would likely be acted upon by kinases 
stimulated by glucose and other nutrients including PKA and PKC. Most studies indicate 
that activation of these PKA can stimulate insulin secretion, but only in the presence of a 
stimulatory fuel source (Komatsu et al., 2002). On the other hand, stimulation of PKC via 
phorbyl esters does stimulate insulin secretion in the absence of nutrients (Nesher et al., 
2002).  
There is a legitimate question as to the physiological significance of iron in 
insulin secretion. Iron within the body and cell are tightly regulated via multiple 
homeostatic mechanisms (Wang and Pantopoulos, 2011). However, as outlined in the 
introduction, there is a wide range of ‘normal’ circulating ferritin levels in humans 
(Fleming et al., 2001). The fact that there is a correlation between iron status and risk for 
developing T2D necessitates determining the role of iron on β-cell function in vivo. It is 
difficult to determine this from studies that have been done, as iron is also known to 
affect insulin action (Fargion et al., 2005). Also, exposure of cells to high levels of iron 
over a prolonged period likely results in apoptosis of β-cells. Our data supports the 
concept that insulin hypersecretion, including that caused by iron, may increase the risk 
of developing T2D.  
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Evolution and genetic considerations for insulin hypersecretion and IR 
 There is a clear genetic component for development of T2D, as children with 
parents who have been previously diagnosed are at greater risk for developing the disease 
themselves (Goran et al., 2004). As previously mentioned, a majority of the genes 
associated with development of T2D reside within the β-cell (Florez, 2008). At some 
point in the evolutionary timeline of humans, the processes/genes that result in insulin 
hypersecretion during nutrient excess must have been selected for and therefore garnered 
a survival advantage. Prior to the advent of agriculture, it was likely that hunter/gatherers 
experienced infrequent and irregular patterns of eating. This led to the hypothesis that 
these “thrifty” genes, while advantageous in hunter/gatherer societies, become 
detrimental in sedentary agricultural societies and lead to the development of western 
diseases including T2D (Neel, 1962). Thus HI may have been helpful in hunter/gatherers 
to store as many nutrients as possible. Those that could store the most nutrients likely 
were likely able to survive during times of starvation. It should be noted that the notion 
that food was insecure in hunter/gatherer societies compared to agricultural societies has 
been challenged (Benyshek and Watson, 2006).  
A new model for β-cell dysfunction 
The progression from obesity and prediabetes to T2D is associated with a loss of 
β-cell glucose responsiveness (Cerasi et al., 1972; Mari et al., 2010). The same is true 
following chronic lipid infusions in rodents (Mason et al., 1999). It is assumed that this 
loss of glucose sensitivity is due to a defect in one or more aspects of the secretory 
pathway. The data presented in Chapter 2 presents an intriguing alternative model to 
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explain the loss of glucose responsiveness under conditions traditionally associated with 
β-cell dysfunction. This model consists of two interrelated phenomenon: (1) a large 
increase in basal secretory capacity and (2) a depletion of insulin granules. β-cells 
secreting insulin at or near maximal rate at basal glucose will not elicit a robust response 
to more glucose. It should be noted that in a diabetic patient, the ‘basal’ glucose 
concentration is already increased. This large increase in basal secretory capacity is 
masked by depletion of mature insulin granules, thus causing only mild basal 
hypersecretion. The depletion in insulin content also causes relative insulin deficiency 
characteristic of T2D and results in hyperglycemia. Figure 1.5 depicts how this β-cell 
failure might develop over time. Evidence for this model can be found in Chapter 2 
(Figure 1.2). Chronic incubation of islets in a high amount of oleate reduced the insulin 
content and caused profound β-cell dysfunction. Islets incubated under these conditions 
exhibited a two-fold increase in basal secretion and only a three-fold first-phase response 
to 11 mM glucose compared to 20-fold in control islets. However, coincubation of the 
islets incubated in oleate with DZ preserved the insulin content and changed the secretory 
profile. Under these conditions, basal secretion was profoundly increased, with no change 
in maximal secretion compared to control islets. Whether the massive increase in basal 
secretion in this model is due to hexokinase activity, sensitization of the exocytotic 
machinery to basal Ca2+ or some other process is unclear at this time. Interestingly, 
overexpression of hexokinase in clonal β-cells reveals a similar phenomenon, namely, 
increased basal secretion with no change in maximal secretion (Ishihara et al., 1994). 
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Evidence in vivo supports this alternative model for the initiation of β-cell failure 
in T2D. Imaging of insulin content in vivo has demonstrated that the transition from 
impaired glucose tolerance to T2D in db/db mice is associated with a sharp reduction in 
insulin content (Zhu et al., 2016). It is not possible from this model to determine if the 
loss of insulin content was due to apoptosis, dedifferentiation, inhibition of insulin 
biosynthesis or hypersecretion not matched by synthesis. Directly inhibiting insulin 
secretion has been shown to preserve insulin content in rats exposed to prolonged 
hyperglycemia, highlighting the notion that the β-cell has a higher capacity for secreting 
insulin than synthesizing it (Sako and Grill, 1990). Overnight inhibition of insulin 
secretion with somatostatin restored the pulse mass of stimulated insulin secretion and 
reduced the circulating proinsulin/insulin ratio (Laedtke et al., 2000). Therefore, many of 
the β-cell secretory defects associated with T2D may be related to a constantly high 
secretory rate. A 24-hour normalization of glucose levels in Type 2 Diabetic patients 
lowers fasting insulin secretion and restores the secretory response of β-cells to an acute 
glucose load, which was nonexistent prior to intervention (Vague and Moulin, 1982). It is 
likely that the lowering of glucose allows for replenishment of β-cell insulin stores 
restoration of a normal response to nutrient secretagogues.  
Preliminary data suggests that chronic exposure of islets to nutrient conditions 
that caused β-cell dysfunction also induced α-cell dysfunction. This is marked by 
excessive glucagon secretion at basal glucose and a failure to adequately suppress 
glucagon secretion at high glucose (Figure 3.5). This is a similar phenotype as observed 
in non-insulin dependent diabetics, in which glucagon remains inappropriately elevated 
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after ingestion of a meal, likely contributing to the impaired glucose tolerance (Del Prato 
and Marchetti, 2004). Hyperglucagonemia is thought to be a significant contributor to the 
hyperglycemia observed in T2D. Incubation of the islets with excess nutrients and DZ 
blocked the hypersecretion of glucagon at basal glucose and improved counter regulatory 
control by high glucose. It is possible that blocking of insulin secretion under these 
conditions preserves the sensitivity of the α-cell to insulin, a known regulator of glucagon 
secretion (Kawamori et al., 2009). DZ itself may potentially mediate these effects as α-
cells express KATP channels (Gromada et al., 2004). Further research will need to be done 
to determine the underlying cause of this phenomenon. Figure 4.5 presents a 
comprehensive model of how diet may induce HI and T2D given the data presented in 
this thesis. 
Inhibition of MGL causes β-cell dysfunction   
 While the previously outlined mechanism for the β-cell dysfunction related to 
T2D is interesting, there are no studies directly testing it. Chapter 3 documents that 
inhibition of MGL, which caused a rise in cellular MAGs, inhibits GSIS. This potentially 
links the β-cell dysfunction of T2D to a specific lipid species. A previous study in our 
laboratory documented that exogenous administration of mono-oleoyl-glycerol to β-cells 
causes an increase in basal insulin secretion that is ROS-dependent (Saadeh et al., 2012). 
We wanted to determine if increasing endogenous MAGs via inhibition of MGL elicited 
the same result. We found that MGL inhibitors reduced GSIS without affecting basal 
insulin secretion. We determined that this reduction in GSIS was likely a result of at least 
two factors: (1) reduced Ca2+ influx and (2) decreased LC-CoA. These two factors may 
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be related as it has been shown that LC-CoA may modulate VDCCs to allow Ca2+ influx 
(Tian et al., 2008).  
 It is expected that the LC-CoA content of islets from diabetic animals would be 
elevated, not reduced. Thus it is difficult to argue that this same mechanism could 
account for the failure of diabetic islets to respond to glucose. It is possible however, that 
buildup of a specific MAG, or other FA species caused by MGL inhibition, could be the 
reason underlying the reduced Ca2+ influx and GSIS. However, a recently published 
paper has documented that inhibition of ABHD6, another β-cell monoglyceride lipase, 
increases insulin secretion in response to glucose (Zhao et al., 2014). The discrepancy 
between these results is not clear at this time, but may have to do with the location of the 
lipase within the cell. ABHD6 is located at the plasma membrane, directly next to the site 
of exocytosis, whereas MGL resides mainly in the cytosol.  
 While we did achieve an increase in cellular MAG species via inhibition of MGL, 
we did not obtain any effect on basal insulin secretion. This contrasts with what our 
laboratory previously observed with exogenous mono-oleoyl-glycerol, namely, an 
increase in basal insulin secretion. While this was determined to be in part ROS-
dependent, it was also associated with an increase in cellular LC-CoA content. Triacsin 
C, an inhibitor of long-chain fatty acyl CoA synthetase, was able to partially inhibit the 
effect of exogenous mono-oleoyl-glycerol on basal insulin secretion (Saadeh et al., 2012). 
In contrast, blockade of MGL reduced cellular LC-CoA content and had no effect on 
basal insulin secretion. Thus, it appears that LC-CoA has a role in regulating basal insulin 
secretion. This work also supports the claim that LC-CoA is an important coupling factor 
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in GSIS. Though at this point we cannot with certainty attribute the effect of MGL 
inhibition on LC-CoA alone.  
Future Directions 
Our long-term goal is to determine 1) whether HI plays a causative role in the 
pathogenesis of T2D and 2) if it can be targeted therapeutically in humans, either 
pharmacologically or nutritionally. To this end we must first establish what causes insulin 
hypersecretion in the first place. We have shown in Chapter 2 that high intracellular lipid 
stores are associated with a left shift in GSIS and Ca2+ sensitivity. Directly testing the 
candidate lipid species outlined in the general discussion to determine precisely what is 
responsible for the left-shift is a top priority. Although it is entirely possible, and even 
probable, that the aforementioned shift is the result of multiple mechanisms involving 
multiple different lipid species. We have not definitively shown that the dose-response 
curve for GSIS is shifted in vivo during obesity. A simple, but worthwhile experiment 
would be to test the time course for how a high-fat diet affects pancreatic insulin content 
and the dose-response for GSIS in rodents. The latter could be accomplished in the 
perfused pancreas or from isolated islets. This would be important to determine if fasting 
glucose is actually stimulatory in these islets, something that could not be tested in vivo 
due to the effects of hypoglycemia in live animals.  
It is clear from our work that depleting intracellular lipid in β-cells will right-shift 
the dose-response curve for GSIS and lower insulin hypersecretion. Therefore, drugs or 
nutritional agents that accomplish this by increasing FA oxidation are intriguing targets. 
We are interested in testing the effect that fibrates, which enhance FA oxidation via 
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peroxisome proliferator-activated receptor α, have on HI in vivo. Additionally, we would 
like to test the effect of diet supplementation with medium-chain FAs, which are 
preferentially oxidized due to their lack of regulated mitochondrial transport. The latter 
could be easily used in humans, as there is unlikely to be detrimental side effects 
associated with use. It is particularly attractive as a potential nutritional therapeutic for 
obesity prior to the onset of diabetes, Unfortunately, it would be difficult to pinpoint the 
effects of these on the β-cell alone, as they undoubtedly will affect other tissues as well. 
Conclusion    
 In conclusion, we have shown in this thesis that a functional change to the 
pancreatic β-cell may be responsible for the HI observed in obesity and the β-cell 
dysfunction characteristic of T2D. Namely, a diet high in fat and simple carbohydrates 
results in a reduced half-maximal concentration for GSIS. Additionally, iron increases a 
constitutive pathway within the β-cell. Prolonged exposure to these conditions reduces 
the ability of the β-cell to properly synthesize, store and secrete insulin leading to β-cell 
failure. Further research will be needed to determine if our findings in vitro also occur in 
vivo.
 	131	
 
Figure 1.5. Model for β-cell failure in the development of T2D.  
In this model, chronic hypersecretion of insulin caused by a left-shift in GSIS and other 
factors results in a reduction in total insulin stores within the beta-cell. This leads to 
relative insulin deficiency given a state of insulin resistance, despite the capacity of the β-
cell for secreting insulin being greater than a normal β-cell. Ultimately, this results in 
hyperglycemia and T2D. 
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Figure 2.5. Increased PIP2 levels in left-shifted cells.  
INS-1 cells cultured chronically in 4 or 11 mM glucose were incubated for 48 hours in 
myoinositol [3H] to label the phospholipid pool. Following extraction, different 
phospholipid species were measured using high performance liquid chromatography as 
detailed here (Sarkes and Rameh, 2010). Left-shifted β-cells had a 300% increase in PIP2 
levels compared to only a 50% increase in PIP. N = 1 experiment. 
 	133	
 
Figure 3.5. Chronic culture in excess nutrients increased basal glucagon secretion. 
Culture of isolated rat islets in control media (11 mM glucose) or control media with 0.4 
mM DZ for 48 hours displayed normal counterregulatory response to glucose. Culture in 
excess oleate (11 mM glucose, 0.2 mM oleate) increased basal glucagon secretion. This 
effect was blunted by coculture of islets in excess FA with 0.4 mM DZ. The experiments 
were done in KREBS buffer after washout of culture conditions as described in the 
methods for insulin secretion. Glucagon was assayed using a radioimmunoassay method 
per the given direction in the kit (EMD Millipore, Darmstadt, Germany). N = 1 
experiment with 3 replicates per condition. 
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Figure 4.5. Simplified model for how nutrient overload can lead to HI and T2D.  
A western-diet high in simple carbohydrates, fat and iron increases lipid synthesis/storage 
and ROS in pancreatic β-cells. This left-shifts the sensitivity of the β-cell to Ca2+ 
sensitivity and GSIS. This left-shift, along with increased β-cell mass and reduced 
clearance of insulin by the liver causes HI. HI and obesity perpetuate one another. This 
leads to IR in peripheral tissues including adipose, liver and muscle. Over time, the β-
cells lose stores and the capacity to respond adequately to glucose due to high basal 
secretion. This leads to a decreased sensitivity of the α-cell to insulin and subsequently 
causes increased basal glucagon secretion and an inability to reduce it when appropriate. 
Together, this leads to hyperglycemia and T2D. 	
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